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Abstract. 
The mucosal surfaces of the gastrointestinal and respiratory tracts are the main interfaces 
between the environment and the host. All two are protected by continuous epithelia that 
prevents the entry of microbes and integrity loss of these epithelia commonly predispose 
to infection. On the other hand the epithelial surfaces provide essential absorptive 
functions for the intake of food and air. SGLT-1 is a co-transporter able to absorb D-
glucose, against a concentration gradient, together with Na+. The expression of SGLT-1 on 
the apical membrane of enterocytes, the cells that line the gut and overlook to the 
intestinal lumen, is fundamental in order to obtain the maximum D-glucose absorption from 
the digested alimentary bolo that transits through the gut. Accumulating data support the 
notion that SGLT1 orchestrates a number of fundamental cellular processes besides its 
canonical absorptive function. Presented results show a novel role of SGLT-1: this protein 
if  appropriately activated modulates the immune response and protect barrier function. 
Our recent findings indicate that the activation of SGLT-1, present at apical membrane of 
enterocytes inhibits bacteria-induced inflammatory processes and lifesaving treatments, 
assuming a role as an immunological player. The main drawback of this activation is the 
high level of glucose that must be administrated (2.5 g/kg) in vivo so to achieve protection. 
In this contest we have developed a new glucoderivatives, named BLF501, able to 
“activate” SGLT-1 in order to achieve the protection against damages induced by LPSs 
while avoiding the disadvantages caused by high glucose concentration.. Thus our new 
synthetic molecule BLF501, acting as a potent activator of SGLT-1 at very low dosages, 
might represent a new pharmacological drug for the treatment of IBD, given the 
cytoprotective and anti-inflammatory effects linked to SGLT-1 activation. Infact BLF501 
stabilizes TJ-protein localization preventing INF-γ/TNF-α. or DSS-mediated degradation. 
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BLF501 is very effective at preventing functional (FD-3 flux) and morphological (TJ protein) 
permeability defects induced by inflammatory or chemically stimuli. In vivo experiments 
utilizing a chemically-induced mouse model of intestinal inflammation, we found that mice 
with acute or chronic colitis BLF-501-treated not presents typical mucosal injury, shows a 
weight recovery and not develops severe clinical symptoms, including bleeding and 
dehydratation. The TJ protein has been reported to be deregulated in IBD. We have 
analyzed occludin and ZO-1  localization in colon tissue of different treatments and we 
have evaluated that intestinal permeability recovery observed with Ussing Chamber 
analysis is mediated by TJ protein protection. Results suggest that the BLF-501-mediated 
action involves stabilization of epithelial junction complex also in vivo. Moreover, we 
observed that activation of pro-inflammatory cytokines, such as TNF-α, and IL-12 in acute 
and chronic colitis was suppressed by oral administration of BLF-501. We have observed 
a marked increase of IL-10 levels in mice treated with BLF-501 and acute and chronic 
cycles of DSS in comparison with DSS alone or with untreated mice. The continuous IL-10 
production from immune system components, guaranteeing an endogenous source of this 
anti-inflammatory cytokine, is able, to down- 
The sodium-dependent glucose transporter-1 (SGLT-1) molecule is expressed by 
intestinal epithelial cells and by pneumocytes. We show here that BLF501, induces 
protective anti-inflammatory effects in lung of mice exposed to aerosolized 
lipopolysaccharide (LPS) or to ovalbumin (OVA), as assessed by analysis of serum, 
brochoalveolar lavage and lung morphology of the mice in both experimental models. 
Findings in the OVA-induced asthma murine model that aerosol and oral, administration of 
BLF501 led to a marked decrease of bronchoalveolar cellular infiltrate and of IL-4, IL-5, 
NO and IgE levels, and increased levels of the anti-inflammatory cytokine IL-10, suggest 
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the promise of SGLT-1 activation by BLF501 as a new approach to improving asthma 
pathology. 
We can conclude thatBLF-501 as ligand of SGLT-1 may be suggested as a new 
pharmacological approach for the treatment of different inflammatory diseases as IBD and 
asthma. 
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1.INTRODUCTION 
1.1 Sodium-dependent glucose transporter-1. 
1.1.1 SGLT-1 and its classical role. 
Luminal content influences intestinal epithelium function and the components of diet 
certainly play a role in the modulation of enterocytes response. The large surface of the 
gut is a wide area that protects and constitutes a easy way to the whole organism for 
pathogen bacteria. On the other hand a so large line on external environment is necessary 
to an appropriate absorption of the nutrients. Often the absorption is a against gradient 
transport because the concentration of nutrient molecules is lower in the lumen than that 
found inside the cells. For this reason a wide range of transporters are evolved in order to 
guarantee the absorption of water and electrolytes, minerals and vitamins, sugars, fatty 
acids, amino-acids and small peptides. The same molecules probably exert different 
effects on the role of IECs in mucosal immunity. D-glucose, in particular, is considered 
prevalently as energetic substrate for cells but a possible role as immuno-modulator is 
poorly analyzed. 
Glucose is among the more abundant monosaccharides in the diet, and its absorption in 
the intestine is mediated by the high-affinity, sodium-dependent glucose transporter 
(SGLT)-1, located in the apical membrane of enterocytes 1. SGLT1 is found in brush 
border membrane of mature enterocytes in the small intestine, with very small amounts 
detectable in the kidneys and the heart. Recently, SGLT1 has also been detected in the 
luminal membrane of intracerebral capillary endothelial cells, where it may participate in 
the transport of glucose across the blood brain barrier 3. During the process of intestinal 
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sugar transport, on the luminal side of the brush border membrane, two Na+ ions bind to 
SGLT1 and produce a conformational change that permits sugar binding. Another 
conformational change allows the substrates to enter the enterocyte. The sugar, followed 
by the Na+, dissociates from SGLT1 because the affinity of the cytosolic sites is low, and 
also because the intracellular concentration of Na+ is low (10 vs 140 mEq/L). The Na+K+-
ATPase in the basolateral membrane is responsible for maintaining the Na+ and K+ 
electrochemical gradients across the cell membrane. A number of factors influence the 
transport function of SGLT1. For example, the regulation of SGLT1 by dietary sugars was 
examined by Miyamoto et 3. Using Northern blotting, they showed that SGLT1 mRNA was 
increased by feeding rats 55% sugar diets containing glucose, galactose, fructose, 
mannose, xylose, or 3-O-methylglucose. Because 3-O-methylglucose is transported by 
SGLT1, but is not metabolized, and because SGLT1 does not transport fructose, mannose 
or xylose, the up-regulation of SGLT1 does not appear to depend on either metabolism or 
transport of the sugar in question. Veyhl et al 4 demonstrated the presence of an 
intracellular regulatory protein (RS1) that may modify the activity of SGLT1. Heat shock 
proteins (hsp) may also play a role in regulating SGLT1 function. A study done in renal 
epithelial cells showed that treatment with hsp70 increased glucose transport, but not the 
abundance of SGLT1 protein5. The increase in sugar transport was inhibited by an 
antibody directed against transforming growth factor β (TGF- β), leading the investigators 
to explore the effect of TGF-β on SGLT1: there was an increase in SGLT1 activity, as well 
as an increase in hsp70 protein when TGF-β was added to the culture media. The 
researchers speculated that hsp70 might stabilize SGLT1 expression in the membrane. 
This concept was supported by confocal microscopy studies, which demonstrated that 
TGF-β appears to move both SGLT1 and Hsp70 near the apical membrane site. The 
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transcription factors hepatocyte nuclear factor- 1 (HNF-1) and Sp1 may also regulate 
SGLT1 5. 
.  
Fig 1 Classical model of intestinal sugar transport. SGLT1 is the sodium dependent 
glucose/galactose transporter on the brush border membrane. The Na+K+-ATPase on the 
basolateral membrane maintains the gradient necessary for the functioning of SGLT1. GLUT5 is a 
facilitative transporter on the brush border membrane which transports fructose into the cell. 
GLUT2 transports glucose, galactose and fructose out of the cell. 
 
1.1.2 SGLT-1 as a new immunological player 
Since 2005 SGLT-1 assumes a novel protective role. SGLT-1 activation loads to a local 
and systemic anti-inflammatory and cytoprotective response, in different inflammatory 
conditions. Firstly the effect of glucose has been analyzed in enterocytes exposed to 
agonists of TLR4 and TLR9. The encouraging in vitro results prompted us to analyze the 
effects of glucose on a systemic inflammatory response syndrome (endotoxic shock) in 
mice. Oral ingestion of glucose was found to protect 100% of mice from lethal endotoxic 
shock induced by intraperitoneal LPS administration; protection was only observed when 
glucose was administered orally, not by i.p. route, suggesting the important role of 
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intestinal epithelial cells6. Subsequently the study investigated the possibility that orally 
administered D-glucose exerts a systemic anti-inflammatory activity on hepatic liver failure. 
In this study7  that D-glucose prevents LPS-induced liver injury, as well as liver injury and 
death induced by acetaminophen overdosing. In both of these models, physiological liver 
morphology is maintained and organ protection was confirmed also by unchanged levels 
of circulating markers of hepatotoxicity, such as ALT or LDH. In addition, D-glucose  was 
found to protect liver from alpha-amanitin intoxication. In this case, however, a second 
signal had to be present in addition to glucose in order to achieve protective efficacy.  
In addition, we observed that the in vivo protections depends from a systemic increase of 
anti-inflammatory cytokine IL- 10 as shown in schematic representation (fig.2). The 
cornerstone of the observed immunomodulatory effects resides in activation of SGLT-1; in 
fact, the glucose analogue 3-OMG, which induces the transporter activity but is not 
metabolized, exerted the same effects as glucose both in vitro and in vivo. Thus, we 
propose that activated SGLT-1, apart from its classical metabolic function, may be a 
promising target for inhibition of bacteria-induced inflammatory processes and life-saving 
treatments, assuming a novel role as an immunological player. 
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Fig. 2 Schematic representation of local and systemic protection by SGLT-1 activation against 
inflammatory damage. 
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1.2 Epithelial barrier and its role in chronic inflammatory 
disease. 
Multicellular organisms, from sea sponges to mammals, require tissue  
compartmentalization to interface with the external environment while supporting 
specialized functions internally. In advanced animals, triploblasts include formation of three 
cell layers during embryogenesis. The endoderm forms the gastrointestinal tract; the 
nervous system and external skin develop from the ectoderm; and the mesoderm gives 
rise to musculoskeletal, genitourinary, and circulatory systems. Each of these layers 
includes cells specialized to establish distinct compartments, including gastrointestinal and 
respiratory epithelia derived from endoderm, epidermal squamous epithelium and 
accessory glands derived from ectoderm, and renal epithelium and vascular endothelium 
derived from mesoderm. Thus, cells that define the interface between the organism and 
the external world are a characteristic of all multicellular eukaryotes. 
Complex multicellular organisms interface with their external enviromments at multiple 
sites, including mucosae of the airway, oral cavity, digestive and genitourinary tracts, and 
the skin. Although the skin is the most visible site of interface, the combined area of the 
mucosal surface is much greater than that of the skin. Epithelial cells that define the  
interface between the organism and external world forms barriers that are essential to life. 
This is particularly true in the intestine, where the epithelial barrier supports nutrient and  
water transport while preventing microbial contamination of the interstitial tissue. 
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1.2.1 Gut epithelial. Cellular components of intestinal mucosa with active immune 
function  
Mucosae are also the primary sites at which the mucosa-associated lymphoid tissue 
(MALT) is exposed to and interacts with the external environment. The magnitude of these 
interactions is greatest in the gastrointestinal tract, which is the largest mucosal surface 
and is also in continuous contact with dietary antigens and diverse microorganisms. Thus, 
mucosal surfaces, particularly in the intestines, are crucial sites of innate and adaptative 
immune regulation. A central mediator of interactions between MALT and the external 
enviroment is the epithelium that cover the mucosa. Epithelial cells establish a active 
barrier between sometimes hostile external enviromments and the internal milieu. 
Gut epithelial surfaces are composed of four cells lineages that arise from a pluripotent 
stem cell progenitor: absorptive globet cells, Paneth cells, enteroendocrine cells and 
enterocytes. Each of which contributes in a unique way to mucosal defence and the 
maintenance of barrier integrity. Goblet cells, found in both the small and large intestines, 
secrete large quantities of mucin, which is composed of highly glycosylated proteins that 
form a protective layer of gel-like mucus over the surface epithelium. Mucus acts trapping 
the vast majority of antigens that, in the intestinal tract, are cleared by peristalsis. By 
keeping microbes moving, these physical factors limit the time available for adherence to 
the epithelia and thus restrict invasion. The importance of mucus gel hydration is shown by 
cystic fibrosis, in which the production of hyperviscous mucus contributes to pulmonary, 
pancreatic and intestinal disease8 Defective mucus production has also been reported in 
various immune-mediated disease, and spontaneous colitis develop in mice that lack 
specific mucin genes9. 
In the small intestine, granulocytic Paneth cells are the key effectors of antimicrobial 
defence. These specialized epithelial cells are situated at the base of small intestinal 
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crypts and harbor secretory granules containing several microbicidal  proteins including 
defensins, lysozyme, and phospholipase A2. Paneth cells sense bacterial proximity and 
react by discharging their microbicidal granule contents into  the gut lumen10. Only the 
microbes that can survive these harsh innate chemical defences have the ability to infect 
and cause disease. 
The epithelial and sub-epithelial region of mucosal surfaces contains abundant 
immunocytes of many varieties. Indeed, in a healthy human adult, the mucosal immune 
system contributes almost 80% of all immunocytes11. The number of immunoglobulin Ig-
secreting cells in this population exceeds by several fold the number of Ig-secreting cells in 
all other lymphoid organs (spleen, bone marrow, and lymph nodes) combined12. 
Importantly, these cells also have the ability to directly sense danger through expression of 
surface receptors specific for conserved microbial products. Under the influence of signals 
from the epithelium, stimulation through these receptors induces these cells to secrete 
cytokines and other modulatory factors. These factors work in concert with the epithelial 
signals to alert and dictate adaptive effector functions13. In this way, cooperation of 
leukocytes and epithelial cells extends the definition of the innate immune system to 
include all cells of the body14. 
Enteroendocrine cells (EEC) form the largest endocrine system in the body. They secrete 
multiple regulatory molecules which control physiological and homeostatic functions, 
particulary postprandial secretion and motility. Their key purpose act as a sensors of 
luminal contents, either in a classical endocrine fashion, or by a paracrine effect on 
proximate cells, notably vagal afferent fibres. They also play a pivotal role in the control of 
food intake, and emerging data add roles in mucosal immunity and repair15. 
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Figure 3 Anatomy of the intestinal immune system. A single layer of intestinal epithelial cells (IECs) 
provides a physical barrier that separates the trillions of commensal bacteria in the intestinal lumen 
from the underlying lamina propria. The IECs lining the lumen are bathed in nutrients, commensal 
bacteria, IgA and goblet cell-produced mucus. Epithelial stem cells proliferate and give rise to 
daughter cells with the potential to proliferate. These IECs then differentiate into villous or colonic 
enterocytes, which absorb nutrients (small intestine) and water (colon). In addition to differentiated 
enterocytes and goblet cells, progenitor IECs differentiate into both enteroendocrine cells, which 
secrete enteric hormones, and Paneth cells at the base of the small intestinal crypts. Beneath the 
IECs, the lamina propria is made up of stromal cells (myofibroblasts), B cells (especially IgA-
producing plasma cells), T cells, macrophages and dendritic cells. Certain subsets of T cells and 
dendritic cells localize between the IECs. The small intestine has regions of specialized epithelium 
termed follicle-associated epithelium and microfold (M) cells that overlie the Peyer’s patches and 
sample the intestinal lumen. IEL, intraepithelial lymphocyte. 
 
Enterocytes, enteroendocrine cells, Paneth cells and globet cells expres Toll-like receptors 
(TLR) that has been shown to be involved in recognition of commensal- and  pathogen 
associated molecular patterns (PAMPs). Moreover, TLR signalling  has been shown to be 
involved in epithelial cell proliferation, IgA production, maintenance of tight junction and 
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antimicrobial peptide expression, which are functions that are crucial for maintaining a 
healthy epithelial barrier. 
IECs are structurally and functionally polarized, with an apical surface facing the intestinal 
lumen and a basolateral surface facing the underlying basement membrane and the 
lamina propria. The polarized structure of IECs is established through exclusive targeting 
of certain membrane proteins to either the apical or basolateral surface and is maintained 
under normal conditions by tight junction complexes. This, together with a layer of mucus 
on the apical surface, establishes a barrier that is generally thought to be impermeable to 
commensal bacteria and other intestinal microorganisms in the gut lumen. However, it is 
likely that a low number of intestinal bacteria, and perhaps other microorganisms such as 
viruses and fungi, traverse the epithelium under steady-state conditions, as gut flora-
derived microorganisms can be cultured from the spleens of mice, especially from mice 
that lack TLR signalling ability. Disruption of the epithelial barrier, such as that which 
occurs during intestinal ulceration or infection with a pathogen, can allow PAMPs to 
access the basolateral surface. 
Given the juxtaposition between IECs and the gut flora, how does the intestinal epithelium 
respond to luminal PAMPs that are largely derived from nonpathogenic commensal 
microorganisms? Consistent with the known function of TLRs, indiscriminate recognition of 
PAMPs by TLRs on the epithelium would be expected to trigger an inflammatory response. 
Such a response to PAMPs from commensal, non-pathogenic bacteria would 
disadvantage the host. Instead, the intestinal epithelium seems to tolerate the presence of 
luminal PAMPs and does not mount an acute inflammatory immune response. Moreover, 
the epithelium require these signals for its normal function and for sensing a breach in its 
barrier.  
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Toll-like receptors (TLRs) are a key group of pattern recognition receptors in mammals. To 
date, 13 mouse and 10 human TLRs have been identified. The members of the TLR family 
are expressed variably throughout the epithelial barrier of the gut. It is still not entirely clear 
which TLRs are expressed in the gut in vivo and which cell types support their expression. 
TLR4, for example, is expressed on several intestinal epithelial cell lines16 and is present 
in intestinal crypt epithelial cells in vivo17. These molecular patterns include bacterial 
cell wall components such as LPS and peptidoglycan or protein components of 
specialized bacterial structures such as flagella. Upon ligand binding, each of the 
TLRs initiates a signalling cascade that trigger  the activation and nuclear translocation of 
the transcription factor NF-kB, which directs expression of proinflammatory genes such as 
IL-8 and IL-6. 
 
1.2.2 Gut epithelial is a dinamic barrier. 
The primary responsibility for mucosal barrier function resides with the epithelial cell 
plasma membrane, which is impermeable to most hydrophilic solutes in the absence of 
specific transporters. Accordingly, direct epithelial cell damage, such as that induced by 
mucosal irritants or cytotoxic agents, including some drugs used for cancer chemotherapy, 
results in a marked loss of barrier function. However, in the presence of an intact epithelial 
cell layer, the paracellular pathway between cells must be sealed. This function is 
mediated by the apical junctional complex, which is composed of the tight junction and 
subjacent adherens junction (fig. 4). Both tight and adherens junctions are supported by a 
dense perijunctional ring of actin and myosin that can regulate barrier function. As implied 
by the name, the adherens junctions, along with desmosomes, provide the strong 
adhesive bonds that maintain cellular proximity and are also a site of intercellular 
communication. Loss of adherens junctions results in disruption of cell–cell and cell– 
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matrix contacts, ineffective epithelial cell polarization and differentiation, and premature 
apoptosis 18. Adherens junctions are composed of cadherins, a family of transmembrane 
proteins that form strong, homotypic interactions with molecules on adjacent cells. 
Adherens junctions are required for assembly of the tight junction, which seals the 
paracellular space. 
 
 
Figure 4 Anatomy of the mucosal barrier. a | The human intestinal mucosa is composed of a 
simple layer of columnar epithelial cells, as well as the underlying lamina propria and muscular 
mucosa. Goblet cells, which synthesize and release mucin, as well as other differentiated epithelial 
cell types, are present. The unstirred layer, which cannot be seen histologically, is located 
immediately above the epithelial cells. The tight junction, a component of the apical junctional 
complex, seals the paracellular space between epithelial cells. Intraepithelial lymphocytes are 
located above the basement membrane, but are subjacent to the tight junction. The lamina propria 
is located beneath the basement membrane and contains immune cells, including macrophages, 
dendritic cells, plasma cells, lamina propria lymphocytes and, in some cases, neutrophils. b | An 
electron micrograph and corresponding line drawing of the junctional complex of an intestinal 
epithelial cell. Just below the base of the microvilli, the plasma membranes of adjacent cells seem 
to fuse at the tight junction, where claudins, zonula occludens 1 (ZO1), occludin and F‑actin 
interact. E‑cadherin, α‑catenin 1, β‑catenin, catenin δ1 (also known as p120 catenin; not shown) 
and F‑actin interact to form the adherens junction. Myosin light chain kinase (MLCK) is associated 
21 
 
with the perijunctional actomyosin ring. Desmosomes, which are located beneath the apical 
junctional complex, are formed by interactions between desmoglein, desmocollin, desmoplakin and 
keratin filaments. 
 
Tight junctions are multi-protein complexes composed of transmembrane proteins, 
peripheral membrane (scaffolding) proteins and regulatory molecules that include kinases 
At present, the most well-understood tight junction proteins are the claudins, a large family 
that includes at least 24 members 19-21. These proteins have four transmembrane helices 
with a very short intracellular amino-terminal sequence and a somewhat longer carboxy-
terminal tail. The first extracellular loop is approximately 50 residues long, although there 
is some variation among claudin family members. More importantly, sequence variation 
within the first extracellular loop determines tight junction charge selectivity22, consistent 
with the view that the array of claudin proteins expressed in a given cell type defines the 
paracellular pore23  through which ions and perhaps nonionic solutes travel. The second 
extracellular loop of claudins is smaller than the first, ranges from 16 to 33 amino acids in 
length, and is poorly characterized  Importantly, almost all claudin proteins terminate with a 
three-aminoacid motif that binds to PDZ domains24. The cytoplasmic plaque, or peripheral 
membrane, proteins of the tight junction include ZO-1 as well as the related proteins ZO-2 
and ZO-325,26. ZO-1 and ZO-2 are each able to direct claudins to developing tight 
junctions; simultaneous elimination of ZO-1 and ZO-2 expression prevents claudin 
recruitment, tight junction formation, and development of barrier function27. 
Occludin, the first transmembrane protein discovered at the tight junction28, continues to 
be enigmatic. An abundance of data making use of cultured cell lines and Xenopus 
embryos suggests that this protein is very important to barrier development and 
regulation29-35. However, occludin knockout embryonic stem cells can differentiate into 
polarized epithelial cells with functional tight junctions, and although occludin knockout 
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mice have severe disease with a complex phenotype 36,37, they do not appear to have 
defects in intestinal transport or barrier function. Thus, although the knockout mice may 
have partially compensated for the absence of occludin, the specific in vivo role of this 
protein remains controversial. Notably, human mutations in the occludin-related tight 
junction protein tricellulin have been linked to autosomal recessive hearing loss 38,39. 
 
Physiological mechanisms of tight junction regulation. The best-characterized example of 
tight junction regulation in response to physiological stimuli remains the reversible increase 
in intestinal paracellular permeability induced by apical Na+-nutrient cotransport40,41. . The 
signal transduction pathway that enhances paracellular permeability following initiation of 
Na+–glucose co-transport has been characterized and includes activation of mitogen-
activated protein kinase cascades, trafficking of Na+–H+-exchange protein 3 (NHE3) to 
the apical membrane and myosin light chain kinase (MLCK) (fig.5).  activation 40. 
Increased NHE3 activity at the apical membrane enhances Na+ absorption, which (along 
with the Na+ absorbed as a result of Na+–glucose co-transport) increases the transcellular 
Na+ gradient and promotes paracellular water absorption. 
This increase in paracellular permeability is thought to allow passive paracellular flux of 
nutrients, along with water, pathways have been saturated. Ultrastructural analyses of tight 
junctions showed that activation of Na+-nutrient cotransport induced condensation of 
perijunctional microfilaments42. This was interpreted as an indicator of actomyosin 
contraction, but at the time the tools needed to study these biochemical events in intact 
tissue did not exist. To circumvent this problem, an in vitro model that recapitulated Na+-
glucose cotransport–induced tight junction regulation was developed through use of 
cultured intestinal epithelial cell monolayers40. Based on the ultrastructural data, 
phosphorylation of myosin II regulatory light chain (MLC), a trigger for actomyosin 
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contraction, was examined and shown to increase following activation of Na+-glucose 
cotransport42. Moreover, pharmacological MLC kinase (MLCK) inhibition prevented both 
MLC phosphorylation and barrier regulation induced by Na+-glucose cotransport in 
cultured monolayers and also blocked barrier regulation in intact intestinal mucosa42. 
These data suggest that MLCK is a critical physiological regulator of tight junction 
permeability. Within months, similar data showing an association of MLCK-dependent 
MLC phosphorylation with increased tight junction permeability induced by 
enteropathogenic Escherichia coli infection were published43,44, suggesting that MLCK-
dependent MLC phosphorylation may be both a physiological and a pathophysiological 
regulator of barrier function. 
 
Fig. 5 Schematic representation of intracellular pathway after SGLT-1 activation that leads to 
physiological acto-myosin ring contractility and water flux across paracellular via. 
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Barrier regulation by immune stimulation The ability of cytokines, such as TNF-α and IFN-
γ, to regulate the function of the tight junction barrier was first described 20 years ago. 
Since then, increased tight junction protein transcription, vesicular removal of proteins from 
the tight junction, tight junction protein degradation, kinase activation and cytoskeletal 
modulation have all been proposed to mediate cytokine-induced loss of tight junction 
barrier function. Although extensive apoptosis of epithelial cells may also cause barrier 
loss, the relevance of single-cell apoptosis to barrier dysfunction remains controversial 
owing to differing results in diverse experimental systems. 
 TNF-α and IFN-γ modify tight junction barrier function in intestinal45,46, renal47, 
pulmonary48 and salivary gland49 epithelia as well as between endothelial cells50. The 
effects of TNF on barrier integrity have been best studied in the gut, where this cytokine 
has a central role in many diseases associated with intestinal epithelial barrier dysfunction, 
including inflammatory bowel disease51, intestinal ischaemia 46,52 and graft-versus host 
disease53. For example, although the effect of therapy with TNF-specific antibodies may be 
largely due to the overall reduction in inflammation. MLCK has been shown to have a 
central role in TNF-α induced epithelial and endothelial barrier dysregulation, both in vitro 
and in vivo 54-58. Similarly, MLCK expression and activity are increased in intestinal 
epithelial cells of patients with inflammatory bowel  disease 59. The degree to which MLCK 
expression and activity are increased correlates with local disease activity, suggesting that 
these processes may be regulated by local cytokine signalling in these patients 59.  
MLCK is also a fundamental intermediate in barrier dysfunction induced by the TNF family 
member LIGHT60, interleukin-1β (IL-1β)61, enteropathogenic Escherichia coli infection43,44, 
Helicobacter pylori infection62, giardiasis63, lipopolysaccharide64,65 and the ethanol 
metabolite acetaldehyde66. Thus, MLCK activation can be viewed as a common final 
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pathway of acute tight junction regulation in response to a broad range of immune and 
infectious stimuli. 
 
Fig. 6 Cytokine regulation of epithelial barrier function. Pro-inflammatory cytokines such as TNF, 
IL-1b, and LIGHT promote barrier dysfunction by inhibiting transcription of junction proteins and 
inducing cytoskeleton mediated redistribution of tight junction proteins. These cytokines promote 
transcription of MLCK, which when activated phosphorylates myosin II, resulting in reorganization 
of tight junction proteins, including endocytic removal from the apical junctional complex. 
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1.2.3 Barrier defects in inflammatory bowel disease. 
Idiopathic IBDs such as Crohn disease and ulcerative colitis occur in clinically 
immunocompetent individuals whose characteristic symptoms and signs arise from a 
robust, cytokine-driven (yet noninfectious) inflammation of the gut67. Crohn disease is 
associated with excess IL-12/IL-23 and IFN-γ/IL-17 production that affects the small bowel 
and colon with discontinuous ulceration and full thickness bowel wall inflammation often 
including granulomas67,68. Patients report gastrointestinal symptoms of abdominal pain, 
diarrhea, and rectal bleeding as well as systemic symptoms of weight loss, fever, and 
fatigue. Crohn disease patients can also develop obstructing structures of the bowel and 
inflammatory connections (fistulae) between segments of bowel or between the bowel and 
skin and other organs. In comparison, ulcerative colitis is associated with excess IL-13 
production, primarily affecting the colon, with a continuous inflammation of the mucosa 
nearly always involving the rectum and extending proximally69.  
It has been proposed that three main features should be present for IBD to occur: (1) a 
genetically susceptible mucosal immune system; (2) an antigen, or pro-inflammatory 
compound, which reaches the gut and can trigger the susceptible immune system; and (3) 
an alteration in gut barrier function which allows antigens to have contact with the mucosal 
immune system  67,68,70. 
Since the studies about Crohn's disease have shown immunological factors underlying 
onset of this disease, the conventional treatments for IBD as corticosteroids, mesalamine, 
and immunosuppressants, provide mostly to block downstream inflammatory events. 
Medical therapy relies on classic antiinflammatory and immunosuppressant drugs: 
corticosteroids, mesalamine compounds, azathioprine, and derivatives of the latter72,73. 
These agents vary in their ability to induce and maintain control of symptoms as well as in 
their tolerability and toxicities. Newer biological drugs such as anti–TNF-α antibodies 
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targeting the general inflammatory cytokine, TNF-α, have added greatly to our ability to 
control IBD, but even this therapy is limited by lack or loss of efficacy and associated 
toxicities51. 
In recent years, several lines of evidence suggested that an increased intestinal 
permeability play a central role in the pathogenesis of IBD. In different animal models of 
Crohn's disease, an increased small intestinal permeability has been shown, even before 
disease expression, and the reversal of this barrier defect can attenuate the disease, 
implying that the increased permeability is not simply an epiphenomenon but rather is an 
important aetiological event. IL-10-deficient and SAMP1/yit mice, which develop 
spontaneous colitis and enteritis, respectively, show increased intestinal permeability 
before disease onset74,75. The suggestion that permeability is merely a sensitive indicator 
of mucosal immune activation would also explain the observation that, during clinical 
remission, increased intestinal permeability is a predictor of relapse in patients with 
Crohn’s disease76. However, barrier dysfunction must also be regarded as a potential 
contributor to disease progression. 
Because a subset of healthy first-degree relatives of patients with Crohn’s disease will 
ultimately develop the disease, and because a similar fraction of these healthy relatives 
have increased intestinal permeability, it has been suggested that tight junction barrier 
dysfunction is one factor that contributes to the development of inflammatory bowel 
disease77. This hypothesis is consistent with a case report documenting increased 
intestinal permeability eight years prior to disease onset in a healthy relative of a patient 
with Crohn’s disease78. In the human condition it is also evident that increased small 
intestinal permeability is commonly observed in populations at high risk of developing 
Crohn's disease. 
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 This would suggest that there is a subtle alteration of function, independent of 
inflammation, which can be visible as an increase in paracellular permeability. This raises 
the possibility that restoration of barrier function may be therapeutic in CD. Consistent with 
this hypothesis, emerging data indicate that inhibition of cytoskeletally mediated barrier 
dysfunction may be able to prevent disease progression. Recently, Zolotarevsky and 
Turner have shown that impaired TJ functionality can be restored in vitro by inhibition of 
MLCK using a short peptide (PIK) that emulates a specific sequence of the regulatory 
domain of this protein79. Thus, peptide-based therapeutics for the treatment of IBD could 
be readily absorbed following oral administration and PIK specifically has the ability to 
reduce the permeability properties of the TJ barrier. Barrier restoration may, therefore, 
represent a non-immunosuppressive approach to achieving or maintain disease remission. 
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1.2.4 Lung epithelial barrier 
Lung epithelium, like intestinal epithelium, provides a physical barrier between host and 
environment, thereby affording passive protection against infectious or  otherwise noxious 
agents. In addition, the lung epithelium may initiate active responses, such as mechanical 
clearance, production of antimicrobial molecules, and participation in the generation of 
adaptive immune responses. Each breath carries in the inhaled air thousands of micro-
organisms and microparticles into the respiratory tract. This exposure appears well 
tolerated by the host, which rarely reacts to this continuous stimulation. Thus, in normal 
conditions, the respiratory tract appears to be well equipped to efficiently eliminate 
exogenous material without generating a major inflammatory or immune response. The 
defence of the respiratory tract against pathogens relies on two distinct mechanisms, 
located in the airways (upper and lower) and the alveolar space, respectively. In the 
airways, mechanical defence appears to predominate and includes the deposition on the 
nasal and oropharyngeal surfaces and elimination through cough, sneezing, and 
mucociliary clearance. In contrast, the alveolar epithelium lacks mucociliary properties and 
therefore relies mostly on the alveolar macrophages to remove particles and micro 
organisms reaching the alveolar space80. In addition, the respiratory tract can also call on 
several protective mechanisms whenever required. For example, the contribution of 
polymorphonuclear neutrophils (PMNs) to the defence of the lung against bacterial 
infection is well recognized, and recent research has elucidated important mechanisms of 
recruitment and activation of PMNs at sites of infection. Another area of research where 
major progress has been made concerns the epithelial cells. Thus, the bronchial epithelial 
cell which has long been recognized as a key element of the mucociliary system is now 
also considered as a pivotal cell in the control of inflammatory and immune responses 
against pathogens and biotoxics. The respiratory epithelium is able to initiate and 
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perpetuate an inflammatory reaction in response to a variety of stimuli. In particular, 
bronchial epithelial cells produce IL-5, IL-8 and growth factors such as granulocyte 
macrophage-colony stimulating factor (GM-CSF), all implicated in attraction and/or 
activation of inflammatory cells 81. Interestingly, IL-8, the most potent neutrophil 
chemoattractant, is released by bronchial epithelial cells in response to bacterial products 
82
. In addition, the epithelium can probably participate in the immune response at an early 
stage after antigen deposition. This participation can occur since epithelial cells are 
recognized as antigen presenting cells, both in the respiratory and digestive mucosa. Also, 
while it is well accepted that inflammatory mediators such as oxidants and proteases can 
damage the airways, conversely, it is likely that remodelling of the bronchial structures (as 
observed in chronic disorders such as asthma, chronic bronchitis or cystic fibrosis) could 
modify the response of the host against inhaled pathogens and toxins. Although 
lymphocytes are scarce in the normal airway and alveolar lumen, they are detected in the 
submucosa of the bronchi and when they are abundant, such as in some pathologies, they 
are sometimes organized in lymphoid tissue called bronchu sassociated lymphoid tissue 
(BALT). A part of their role is related to the mucosal humoral immune response and more 
specifically to the production of immunoglobulin (Ig)-A. The defence mechanisms of the 
bronchial tree and lung parenchyma against infection, often associated with an 
inflammatory or immune response, have been the topic of extensive reviews and of 
several workshops 83. However, the most recent information on the role of the mucosal 
humoral immune system (namely the secretory IgA system) has rarely been addressed in 
the literature devoted to the lung. 
Receptors for microbial ligands in lung 
The pulmonary epithelium contributes to lung defense in several ways. First, it serves as a 
structural barrier and in clearance of inhaled particles and microbes by the ‘muco-ciliary 
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escalator’. As in other organs, lung epithelial cells form intercellular junctions (tight and 
adherens junctions) that divide the epithelial cells into apical and basal surfaces and 
restrict the passive movement of particles and molecules across the epithelium. In 
addition, epithelial cells actively participate in the inflammatory response and are capable 
of mounting an immune response and potentially even killing microbial pathogens by 
internalization of organisms and secretion of cytotoxic and anti-microbial peptides84,85. 
Epithelial cells can be stimulated by bacterial components, such as LPS, and by cytokines 
such as TNF-α and IL-1β espresse by cells of the immune system as well as by some 
parenchymal cells that recognize conserved epitopes in microbial pathogens. Analogously 
to intestinal epithelial cells, in lung the cells that have a direct contact with the external 
environment express receptors able to recognize bacterial and harmful agents and to 
stimulate the immune response.  
Antimicrobial peptides in respiratory system 
All of the β-defensins are present in the respiratory system. These AMPs are expressed at 
various levels in the epithelia of trachea and lung as well as in the serous cells of the 
submucosal glands. Cathelicidins are also present in the conducting airway epithelium, 
pulmonary epithelium, and submucosal glands 86. Functionally, the importance of these 
AMPs in the respiratory system has been suggested by several investigations. Mice 
deficient in β-defensin 1, for example, show decreased ability to clear Haemophilus 
influenzae instilled into their lungs 87. 
32 
 
2. MATERIALS AND METHODS. 
BLF501 role in intestinal inflammation: in vitro and in vivo 
experiments. 
2.1 In vitro: 
2.1.1 Cell lines and treatments. 
HT-29 and CaCo-2 human colorectal carcinoma epithelial cells were obtained from the 
American Type Culture Collection (Manassas, VA). HT-29 cells were maintained in 
Dulbecco’s modified Eagle’s medium (DMEM) (Sigma-Aldrich, St. Louis, MO) with L-
glutamine, supplemented with 10% fetal bovine serum (FBS) (Gibco, Invitrogen Corp., 
Auckland, NZ), 200 U/ml penicillin and 200 µg/ml streptomycin (Sigma-Aldrich) (complete 
medium). CaCo-2 cells were maintained in DMEM with L-glutamine, supplemented with 
10% FBS, 200 U/ml penicillin and 200 µg/ml streptomycin, 1 mmol/L sodium pyruvate, 1% 
non-essential amino acids. Cells were grown at 37°C  in a 5% CO2 humidified atmosphere. 
To analyze effects of BLF501 on IL-8 release after LPS stimulation HT29 cells were 
cultured for 18 h in complete medium, or in medium with synthetic molecules (50mg/l – 
0.05 µg/l concentration), before stimulation with LPS (1 µg/ml) for 6 h. Supernatants were 
collected at the end of treatment and stored at -80°C. 
Caco-2 cells were grown as monolayers on collagen-coated polycarbonate membrane 
Transwell supports (Corning-Costar, Acton, MA) and  used 17 to 20 days after confluence. 
Transwell supports with 0.33 cm2 area were used for paracellular flux assays. Caco-2 
monolayer were cultured for 24 hours in complete medium, or in medium additioned with 
BLF501 5 µg/l. Other Caco2 monolayers were incubated with IFN-γ (10 ng/ml) for 16 hours 
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and after with TNF-α (2.5 ng/ml) for 8 hours. Cythokines were added to the basal chamber 
without manipulating the apical media.. In other samples, Caco-2 monolayers were 
cultured with BLF501 5 µg/l, with concomitant INF-γ plus TNF-α administration, for 24 h 
total. 
Moreover,. Caco-2 monolayer were cultured for 24 hours in complete medium, or in 
medium additioned with BLF501 5 µg/l. Other Caco2 monolayers were incubated with only 
DSS 5%-added medium for 24 hours or with BLF501 5 µg/l and DSS 5%. 
Same treatments were performed in Caco-2 grown in coverslips on 24 well in order to 
detect TJ protein with immunofluorescence methods. 
2.1.2 Paracellular Flux Assay. 
 Flux of isothiocynate-labeled dextran (molecular weight, 3kD, Molecular Probes, Eugene, 
OR) was evaluated across Caco-2 monolayer. Epithelial monolayers were washed free of 
media and equilibrated with Hanks bilance salt solution (HBSS from Sigma) at 37°C prior 
to addition of fluorescent tracer. Apical medium was removed and 250 µl of FD-3 1 mg/ml 
(diluted in HBSS) was added to the apical chamber. At 30 minutes and 90 minutes after 
the end of different treatments monolayer recevoirs were agitated by pipetting and 50 µl 
samples were removed from basal chambre. Fluorescent intensity (excitation, 485 nm; 
emission, 530 nm) was measured on a fluorescent plate reader (CitofluorTM 2300, Millipore 
Inc. Bedford, MA). Tracer concentrations were determinated from standard curves 
generated by serial diluition of known concentrations of FD-3 in HBSS. All data were 
normalized for background fluorescence by substraction of fluorescence intensity of 
semples collected from monolayer incubated in buffer only, without addition of fluorescent 
tracer.
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2.1.3. Immunofluorescence microscopy analysis 
Caco-2 cells were grown as monolayer on coverslips in 24-well plates. For occludin 
detection monolayers were permeabilized in ice for 2 minutes with 0.2% Triton X-100 in 
Tris-HCl and fixed with 3.7% paraformaldehyde 30 minutes at room temperature. After 
incubation for 1 hour in ice with rabbit anti-occludin (from Zymed, Invitrogen) antibody, 
Caco2 monolayers were washed and incubated with 546 Alexa conjugated secondary 
antibody goat anti-rabbit (from Molecular Probes)  for 45 min at room temperature.  
For staining of ZO-1, Caco-2 monolayers were permeabilized and fixed in methanol for 10 
min at -20°C and after were incubated with rabbit a nti-ZO-1 antibody (from Zymed, 
Invitrogen) for 1 hour at room temperature, followed by incubation with 546 Alexa 
conjugated secondary antibody for 45 min.  
In staining of both TJ protein nuclei were stained with 4’, 6’-diamidino-2-phenylindole 
(DAPI) and mounted with Mowiol 4-88 (from Calbiochem). Monolayers 
immunofluorescence was observed with a Nikon Eclipse 80i Video Confoccal microscope 
equipped with a digital Nikon DS-L1 camera. 
2.1.4 Knockdown of SGLT-1 using small interfering RNA 
SGLT-1 was silenced by small interfering RNA (siRNA) transfection. Briefly, HT-29 cells (3 
x 105/well) seeded in 6-well plates at 60–80% of confluence were washed in Optimem 
(Invitrogen Life Technologies) medium and then transfected with a pool of siRNA 
oligonucleotides targeting human SGLT-1 or a scrambled RNA duplex (Santa Cruz), at a 
final concentration of 100 nM. Six µg/µl Lipofectamine 2000 (Invitrogen) were used as 
transfection reagent. After 24 h, the transfection mixture was aspirated, replaced with 
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culture medium and the cells has been treated for 24 h with BLF501 (50 mg/l) and TLR 
agonists (LPS) as reported above. 
2.2 In vivo 
2.2.1 Mice  
C57BL/6 female mice were purchased from Charles River, Italy (Head Office Wilmington, 
MA). Mice were housed under specific pathogen-free conditions, maintained at constant 
temperature and humidity, with food and water given ad libitum, and used at 8-12 weeks of 
age. Experimental protocols were approved by the Ethics Committee for Animal 
Experimentation of Istituto Nazionale Tumori, Milano, and carried out according to 
guidelines of the United Kingdom Co-ordinating Committee on Cancer Research for 
animal welfare in experimental neoplasia(1998). 
2.2.2 Experimental model of sepsis. 
For the experimental model of sepsis, mice (n=10) were injected i.p. with 250 µg/kg of LPS 
and 1 g/kg of GalNH2 (D-galactosamine), with or without oral pretreatment with BLF501 25 
or 13,43 or 7,57 or 4,3 or 2,5 or 0,025 µg/kg 1 h before LPS/GalNH2 administration. One 
control group was treated with sterile water,and another with only BLF501 (25 μg/kg). 
Animal deaths were recorded in the first 24 h and in the week following LPS treatment. 
2.2.3 Induction of acute and chronic colitis 
Mice weighting 20-22 g  received 2% dextran sodium salt (molecular mass 40 kilodaltons, 
MP Biomedicals, Irvine, CA) ad libitum in filter-purified drinking water for 7 days. For 
treatments studies mice undergoing DSS from day 4 at day 7 received oral administration 
of BLF501 250 µg/kg or 25 µg/kg or 2,5 µg/kg or glucose 2,5 g/kg once day. BLF501 and 
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glucose were administrated with a steril stomach tube In other mice groups received only 
BLF501 250 µg/kg or 25 µg/kg or 2,5 µg/kg or glucose 2,5 g/kg. One group received only 
DSS 2% in drinking water (as rapresented inn table 1 and 2). 
Day 1 Day 2 Day 3 Day 4 Day 5 Day 6 Day 7 Day 8 
DSS 2% DSS 2% DSS 2% DSS 2% 
+BLF501 
or 
glucose 
DSS 2% 
+BLF501 
or 
glucose 
DSS 2% 
+BLF501 
or 
glucose 
DSS 2% 
+BLF501 
or 
glucose 
Sacrifice 
Table 1.Schematic presentation of different treatments in the time. Mice received DSS 2% in 
drinking water. BLF501 250 µg/kg or 25 µg/kg or 2,5 µg/kg or glucose 2,5 g/kg were administrated 
(diluited in physiological solution) once per day at day 4, 5, 6, 7 and at 8th mice were sacrificated. 
Groups Treatment 
1 Untreated 
2 DSS 2% only 
3 DSS 2% + Glucose 2,5 g/kg 
4 DSS 2% + BLF501 250 µg/kg 
5 DSS 2% + BLF501 25 µg/kg 
6 DSS 2% + BLF501 2,5 µg/kg 
7 Glucose 2,5 g/kg only 
8 BLF501 250 µg/kg 
9 BLF501 25 µg/kg 
10 DSS 2% + physiological solution 
Table 2 Schematic representation mice groups. 5 mice/groups. 
To induce chronic colitis four groups of 10 mice/groups mice received three cycles of DSS 
2%. Each cycle consists of 2% DSS dissolved in filter-purified drinking water for 7 days, 
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followed by a 14 days interval with normal water administration. After ten days from the 
last DSS cycle we started different treatments. 
 The first group of animals (control group) received normal drinking water only, during the 
whole time of the experiment. The second group of 12 mice received only three cycles of 
treatment with DSS, as previously described, and no any further treatment. Four mice of 
this group were sacrificated one week after DSS cycle completion; four mice of this group 
were sacrificated two weeks after DSS cycle completion; and 4 mice were sacrificated 
after three weeks. 
 After DSS cycles completion, third mice group received oral administration of 25 µg/kg 
BLF501 four times/week for one week; forth received 25 µg/kg BLF501 four times/week for 
two consecutive weeks; and fifth received 25 µg/kg BLF501 four times/week for three 
consecutive weeks.  
Groups Treatments 
1 Untreated 
2 DSS 2% +physiological solution 
3 DSS 2%+ BLF501 25 µg/kg for 1 week 
4 DSS 2% + BLF501 25 µg/kg for two week 
5 DSS 2% + BLF501 25 µg/kg for three weeks 
Table 2 Schematic representation mice groups. 12 mice in group 1. In goups 2, 3, 4 and 5 10 
mice/group. 
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TREAT. DSS H2O DSS H2O DSS H2O BLF501 
25 µg/kg 
Death 
Group3 
and 2 
BLF501 
25 µg/kg 
Death 
Group4 
and 2 
BLF501 
25 µg/kg 
Death 
Group5 
and 2 
N days 7 14 7 14 7 10 7 X 7 X 7 X 
Table 3 Schematic presentation of different treatments time. N days is for number days of water 
DSS 2% added or water only administration. After ten days of the last DSS cycle BLF501 was 
orally administrated 4 times/week for 1 or 2 or 3 consecutive week. X is for sacrifice day. 
Evaluation of intestinal inflammation in acute and chronic colitis 
Acute colitis was scored daily using standard parametres that includes evaluation of body 
weight and stool consistence. Body weight of mice was registered daily at 5.00 p.m.. Stool 
consistence was valuated daily, but comparative analysis between differents groups was 
conducted at the end of experiments. 
Score Stool consistence Blood 
0 Normal No visible 
1 Soft but still formed No visible 
2 Very soft Blood traces in stool visible 
3 Diarrhea Rectal bleeding 
Table 4 Scoring system for the comparative analysis of stool consistence. 
At the end of treatments the colon of mice was cut close to the ileo-cecal valve and 
rectum, and the length was measured with and .for acute colitis experiment  photos were 
captured. 
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Ussing Chamber analysis.. 
In order to measure the colon permeability in 5 mice/group, organ segments were 
mounted between the two chambers of a Ussing System (0.125 cm2 opening). Two 
calomel voltage-sensitive electrodes and two Ag-AgCl current passing electrodes (EVC-
4000 World Precision Instrument Inc., Sarasota, FL) were connected to the Ussing 
chamber via agar bridges. Both the mucosal and serosal sides of the chamber were 
connected to sterilized circulating reservoirs containing 10 ml of oxygenated Krebs buffer 
(115 mM NaCl, 8 mM KCl, 1.25 mM CaCl2, 1.2 mM MgCl2, 2 mM KH2PO4, and 225 mM 
NaHCO3; pH 7.35). The buffers were maintained at 37°C by a heated water jacket and will 
circulate by a gas lift column of 95% oxygen/5% CO2. Glucose (5.5 mM) was added to the 
serosal and mucosal sides. Colonic membrane mounted in the Ussing chamber, the 
system was allowed to stabilize for 20 minutes, in order to test the system functionality and 
the integrity of the colonic mucosal membrane. Trans-epithelial electrical potential 
difference in millivolt across the mucosal membrane was measured directly, while the 
trans-membrane resistance was calculated indirectly as ohms x cm2, using Ohm's law. 
Organotypic culture of colon. 
Colon from 3 mice/group was excised, opened, and cut transversely into 3 parts. Each 
segments was washed in cold phosphate-buffered saline (PBS) containing penicillin, 
streptomycin, and amphotericin B (Cambrex; BioWhittaker, Walkersville, MD) and 
incubated in serum-free RPMI 1640 medium containing 0.1% penicillin, streptomycin, and 
amphotericin B at 37°C in 5% CO 2. After 2 hours, supernatants were collected, 
centrifuged, and stored at -80°C to cytokines. 
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Histological evaluation of colitis severity. 
Murine colon specimens of 5 mice/group will be fixed in 10% neutral buffered formalin, 
embedded in paraffin, sectioned at 4 µm and collected on silanized slides.  
Histopathological analysis using hematoxylin-eosin-stained sections of distal colon 
samples of mice were performed. Samples were observed with a Nikon Eclipse 80i 
microscope equipped with a digital Nikon DS-L1 camera. To quantify/evaluate acute and 
chronic colitis-associated histological alteration in the colon we used a scoring system, 
provided in table 5. 
Score Histologic changes 
0 No evidence of inflammation 
1 Low level of inflammation with scattered infiltranting mononuclear cells 
2 Moderate inflammation with multiple foci 
3 High level of inflammation with increate vascular density and marked wall thickening 
4 Maximal severity of inflammation with transmural leukocyte infiltration and loss of globet 
cells. 
Table 5 Scoring system for inflammation associated histological changes in the colon 
2.2.4 Enzyme-linked immunosorbent assay. 
In HT29 treatments concentrations of IL-8 were evaluated using ELISA kits obtained 
respectively from Endogen (Woburn, MA), and Pierce Biotechnology (Rockford, IL) and 
carried out according to the manufacturers' instructions. 
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Evaluation TNF-α, IL-10 and IL-12 in supernatants of organ cultures and in murine plasma 
samples were obtained using ELISA kits respectively from R & D Systems (Minneapolis, 
MN), Endogen (Woburn, MA), and Pierce Biotechnology (Rockford, IL) and carried out 
according to the manufacturers' instructions. . Plasma samples were collected from each 
mouse before sacrifice , for cytokines evaluation. 
2.2.5 Immunofluorescence analysis in tissue 
Murine colon specimens were fixed in 10% neutral buffered formalin, embedded in 
paraffin, sectioned at 4 µm and collected on silanizated slides; samples were 
deparaffinized, rehydrated, and incubated for 10 minutes at 37 °C in a humidified chamber 
with protease type XIV 2 mg/ml (from Sigma) in Tris HCl; samples were then incubated 
with glycine 0,1 M for 20 minutes at room temperature, washed with TrisHCl + Triton X-
100 0.01%, incubated with NaBH4 0.5mg/ml for 20 minutes at room temperature, washed 
with TrisHCl + Triton X-100 0.01%, incubated with Image-IT FX signal enhancer 
(Invitrogen) for 30 minutes, blocked with 2% goat serum for 20 minutes at room 
temperature and incubated with rabbit anti-occludin or anti-ZO-1 antibody 4 µg/ml (both 
from Invitrogen). Incubation with secondary antibody 546 Alexa conjugated goat anti-rabbit 
and staining of the nuclei with DAPI were performer. Samples were observed with a Nikon 
Eclipse 80i microscope equipped with a digital Nikon DS-L1 camera. 
3.5 Statistical analysis. 
Student’s t-test (paired two-tailed) and GraphPad Prism software (GraphPad Prism 
Software Inc., San Diego, CA) were used for comparisons between groups. Differences 
were considered significant at p<0.005. 
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3. MATERIALS AND METHODS. 
BLF501 role in lung inflammation 
3.1 Cell lines and treatments. 
A549 human lung carcinoma epithelial cells (derived from type II pneumocytes), HT-29 
and CaCo-2 human colorectal carcinoma epithelial cells, and 16-HBE human bronchial 
epithelial cells were obtained from the American Type Culture Collection (Manassas, VA). 
A549, HT-29 and 16-HBE cells were maintained in Dulbecco’s modified Eagle’s medium 
(DMEM) (Sigma-Aldrich, St. Louis, MO) with L-glutamine, supplemented with 10% fetal 
bovine serum (FBS) (Gibco, Invitrogen Corp., Auckland, NZ), 200 U/ml penicillin and 200 
µg/ml streptomycin (Sigma-Aldrich) (complete medium). CaCo-2 cells were maintained in 
DMEM with L-glutamine, supplemented with 10% FBS, 200 U/ml penicillin and 200 µg/ml 
streptomycin, 1 mmol/L sodium pyruvate, 1% non-essential amino acids. Cells were grown 
at 37°C in a 5% CO 2 humidified atmosphere. HUH 7 human liver hepatoma cells (kindly 
provided by  F. Marincola, National Institutes of Health, Bethesda, MD) were maintained in 
DMEM with L-glutamine, supplemented with 10% FBS, 10 mM Hepes, 200 U/ml penicillin 
and 200 µg/ml streptomycin. 
A549, 16-HBE and HT-29 cells were cultured for 18 h in complete medium or in complete 
medium supplemented with high D-glucose concentration (5 g/L) (Merck, Darmstadt, 
Germany) or in medium containing BLF501 (50 µg/L) before stimulation with LPS from 
Pseudomonas aeruginosa (100 µg/ml) (Sigma-Aldrich) for 6 h. Supernatants were 
collected at the end of treatment and stored at -80°C. In some experiments with HT-29 
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cells, TNF-α (Peprotech Inc., Rocky Hill, NJ) was added at 50 ng/ml for 6 h at the end of 
the 18-h culture period. 
3.1.1 Coculture of HT-29 and human MoDCs. 
Human PBMCs were isolated by Ficoll-Paque density gradient centrifugation of buffy coats 
obtained from healthy volunteers (Fondazione IRCCS, Istituto Nazionale dei Tumori, 
Milan, Italy). CD14+ monocytes were positively selected using anti-CD14+ microbeads. 
Monocytes were induced to differentiate to immature MoDCs in 5- to 6-day culture in RPMI 
1640 complete medium supplemented with 50 ng/ml GM-CSF and 50 ng/ml IL-4. Purity of 
monocytes and MoDCs, routinely checked by flow cytometric analysis using anti-CD14-
FITC (M5E2) and anti-CD1a-FITC (HI149) (both from BD Bioscience Pharmingen, San 
Diego, CA), was more than 90%. MoDCs cells (1x105) were cultured in a multi-well 
support for 1 day, and confluent HT-29 cells grown in the upper part of a Transwell growth 
support (Millipore, Billerica, MA) were added to the same wells; cells were incubated for 18 
h with BLF501 and stimulated for 6 h with TNF-α as described above. Cells treated with 
BLF501 alone or TNF-α alone or left untreated served as controls.  Supernatants were 
collected and analyzed as reported below. 
3.1.2 Small interfering RNA (siRNA). 
Expression of SGLT-1 was silenced by transfection with siRNA. Briefly, cells (2x105/well) 
seeded in 6-well plates, harvested at 60-80% confluence, washed in Optimem medium 
(Invitrogen Corp.), and transfected with a pool of siRNA oligonucleotides targeting human 
SGLT-1 mRNA or a scrambled RNA duplex (Santa Cruz Biotechnology Inc., Santa Cruz, 
CA) at a final concentration of 100 nM using Lipofectin 200 (6 µg/αµl; Invitrogen Corp.) as 
transfection reagent. After 24 h, the transfection mixture was aspirated, replaced with 
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culture medium, and cells were incubated for 24 h as above with BLF501 or glucose in the 
presence of LPS or TNF-α. 
3.2 Mice and in vivo treatments 
3.2.1 Exposure of mice to aerosolized LPS. 
Male 8 weeks-old C57BL/6 mice (purchased from Charles River, Calco, Italy) were 
maintained under specific pathogen-free conditions. Experimental protocols were 
approved by the Ethics Committee for Animal Experimentation of the Istituto Nazionale 
Tumori, Milan, Italy according to UKCCCR guidelines. Mice (n=5/group) were exposed to 
aerosolized LPS from Pseudomonas aeruginosa in a whole-animal exposure system, in 
which animals were placed in wire-mesh cages within a 55-l Plexiglas cylinder connected 
via 10-cm ducting to a 16-l aerosol chamber. Airflow through the system was maintained at 
20 l/min by negative pressure. Aerosols were generated from twin jet nebulizers (Salter 
Labs, Arvin, CA), each containing 3 ml of LPS suspension (3 mg/ml) and driven by forced 
air at 15-18 psi. After 30 min, the chamber was purged with ambient air and mice were 
returned to their microisolator cages. Some mice were concomitantly exposed to 
aerosolized BLF501 (266 ng/ml, for a total of 3 ml). These treatments were carried out 
daily for 5 consecutive days. In another experiment, mice were treated orally with BLF501 
before exposure to aerosolized LPS. 
3.2.2 Asthma model. 
Male 8 weeks-old C57BL/6 mice (n=5/group) were immunized i.p. weekly for 2 weeks with 
100 µg ovalbumin (OVA grade V; Sigma-Aldrich) and 500 µg aluminum hydroxide (Alum, 
Sigma-Aldrich). Two weeks after the first immunization, mice were challenged for 25 min 
with an aerosol of 5% (wt/vol) OVA in PBS each day for 5 consecutive days. A second 
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group of mice was analogously treated with OVA but additionally treated with aerosolized 
BLF501 (266 ng/ml, total of 3 ml, diluted in saline solution) during the 5 days of 
aerosolized OVA challenge. A third group of mice was analogously treated with OVA and 
received OVA plus oral BLF501 (25 µg/kg, diluted in saline solution) both on the days of 
i.p. OVA challenge and during the 5 days of aerosolized OVA challenge. A group of mice 
was also injected i.p. with a neutralizing anti-TNF-α antibody (R & D System, Minneapolis, 
MN) at 15 g/mouse during the 4th and 5th day of OVA plus BLF501 administration. Two 
hours after the last inhalation, blood samples were collected retroorbitally and mice were 
sacrificed and BALF performed. 
3.2.3 Bronchoalveolar lavage (BALF). 
BALF was performed by 3 instilliations of 1 ml saline into the lungs through a tracheal 
cannula, followed by gentle aspiration of the fluid and filtration of the recovered fluid 
through double-layer gauze to remove mucus. The resulting BALF was centrifuged (1000 
rpm, 4ºC, 10 min), supernatants were collected and stored at –80ºC, while cells were  
formalin-fixed with the addition of sucrose (VWR International, Poole, England). BALFs 
were assessed for total cell counts, and aliquots were pelleted on glass slides by 
cytocentrifugation (Shandon Inc., Pittsburgh, PA). Differential counts were performed on 
Giemsa (Fluka, St. Gallen, Switzerland)-stained cytospins. 
3.2.4 Hematoxylin-eosin staining. 
Lung samples collected from mice and fixed in 10% paraformaldehyde and embedded in 
paraffin were sectioned (4 µm thickness}, deparaffinized, rehydrated, stained with 
hematoxylin and eosin, and mounted in Entellan® (Merck). Slides were observed under a 
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Nikon Eclipse 80i microscope equipped with a digital Nikon DS-L1 camera (Nikon 
Instruments, Firenze, Italy). 
3.2.5 Immunohistochemistry. 
Expression of ICAM-1 and caveolin-1 in lung samples was assessed 
immunohistochemically. Briefly, 4-µm sections of paraffin-embedded samples were 
deparaffinized and endogenous peroxidases were quenched for 20 min with 0.3% (v/v) 
hydrogen peroxide in PBS. Sections were incubated for 1 hour at room temperature with 
goat anti-mouse ICAM-1 (1:10 in PBS, R&D Systems) or rabbit anti-mouse caveolin-1 
(1:200 in PBS, Santa Cruz Biotechnology, Inc.) polyclonal antibodies, washed with PBS, 
and incubated with secondary antibodies at room temperature  Specific labeling was 
detected with a DAB Substrate Kit for peroxidase (Vector Laboratories). 
3.2.6 Immunofluorescence assay. 
Antigen retrieval was carried out in mouse lung sections, followed by sequential incubation 
with 0.1 M glycine buffer and sodium tetrahydroborate solution, each for 20 min at room 
temperature. Immunofluorescence detection of SGLT-1 expression on pneumocytes was 
carried out using polyclonal anti-SGLT-1 antibody (Millipore), diluted 1:1000 in PBS, for 1 h 
at room temperature, followed by addition of goat anti-rabbit antibody Alexa 488 
(Invitrogen Corp.), diluted 1:200 in PBS and 3% BSA,  for 30 min at room temperature. 
Nuclei were counterstained with 4,6-diamidino-2-phenylindole and slides were mounted 
with Mowiol mounting medium. 
3.2.7 Isolation of murine dendritic cells. 
Lung tissue was placed in PBS, DTT (145 µg/ml) and EDTA (0.37 mg/ml), dissected, 
digested with collagenase type 2 (Sigma Aldrich) (final concentration of 10 mg/ml in 
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RPMI), and DNAse (bovine pancreatic DNAse, Sigma-Aldrich) (final concentration of 25 
mg/ml ) for 60 min at 37°C with gentle shaking. Aft er gentle disruption using a 2-ml syringe 
to produce a single-cell suspension, samples were centrifuged at 1500 rpm for 5 min at 4° 
C, washed with PBS containing 0.5% FBS, and cells were counted.  Samples were 
incubated with anti-Fc receptor antibody (Miltenyi Biotec S.r.l., Calderara di Reno, Italy), 
followed by incubation at the appropriate ratio with MACS CD11c microbeads (Miltenyi 
Biotec S.r.l.) for 15 min at 4°C. After further was hes with PBS containing 0.5% FBS, cells 
were separated by passing the antibody-coated cell suspension over a VS+ column on a 
SuperMACS magnetic cell separator (all from Miltenyi Biotec S.r.l.), flushed with PBS-
0.5% FBS to collect CD11e-positive cells, washed with RPMI medium, counted and plated 
in vitro at constant cell density for 18 h, when supernatants were harvested for analysis of 
cytokine levels. 
3.3 Enzyme-linked immunosorbent assays (ELISA). 
Levels of KC, NO, IgE, IL-4, IL-5, IL-8, IL-10, and TNF-α in serum samples or culture 
supernatants were quantitated using ELISA kits (Quantikine, R&D Systems, Minneapolis, 
MN; Promega Corp., Madison, WI; MD Biosciences, Zürich, Switzerland; Endogen, 
Woburn, MA; BD Biosciences, San Diego, CA), according to the manufacturers' 
instructions. Enzymatic reactions were detected in an automatic microplate photometer 
(Multiskan Ascent, Thermo Electron Corporation, Vantaa, Finland). 
3.3.1 hsp/hsp25 ELISA. 
To quantitate expression of hsp27 and its murine homologue hsp25, 96-well plates (NUNC 
Thermo Fisher Scientific Inc., Rochester, NY) were coated with 10 µl/well of HT29 cell 
supernatant or mouse serum, left overnight at 4°C, washed 3 times with PBS, 0.5% Tween 
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20, and incubated for 60 min at room temperature with primary rabbit anti-hsp27 antibody 
(Abcam, Cambridge, UK) (cross-reacts with mouse hsp25) diluted 1:2,000 in assay diluent 
(PBS, 0.5% Tween 20, 5% FBS, 100 µl/well); after 3 further washes, plates were 
incubated for 60 min at room temperature with secondary biotinylated anti-rabbit antibody 
(Vector Laboratories, Burlingame, CA) diluted 1:1000 in assay diluent (100 µl/well), 
washed 3 times, and incubated with streptavidin-conjugated horseradish peroxidase (SA-
HRP, 1:250 in assay diluent, 100 l/well) for 30 min. After seven further washes, 100 µl of 
tetramethylbenzidine (TMB) substrate (0.1 mg/ml 0.05 M phosphate-citrate buffer, pH 5.0) 
was added to each well and incubated at room temperature for 50 min, when the reaction 
was stopped by addition of 20 µl of 2 M H2SO4.  Plates were examined at 450 nm 
(absorbance filter) using the automatic microplate photometer. 
3.4 Western blot analysis. 
Cell protein extracts were quantified using the BCA Protein Assay Kit (Pierce, Rockford, 
IL). Total proteins (15 µg) were fractionated on 8-12% acrylamide (BIO-RAD Labs., 
Hercules, CA) slab gels containing 0.1% SDS (Sigma-Aldrich) and transferred onto a 
nitrocellulose filter (Amersham Biosciences, Buckinghamshire, England) by electroblotting. 
Filters were incubated for 1 h in TBS, 1% Tween-20 (Sigma-Aldrich), blocked with 5% milk 
powder to prevent non-specific binding, and incubated overnight at 4°C with rabbit 
polyclonal anti-SGLT-1 antibody (Chemicon International, Temecula, CA) diluted 1:5000 in 
TBS, or at room temperature with polyclonal rabbit anti-caveolin-1 antibody (Santa Cruz 
Biotechnology Inc.) diluted 1:200 in TBS, washed three times for 10 min each in TBS and 
1% Tween-20, and incubated with the appropriate peroxidase-conjugated secondary 
antibody at room temperature. Bands were visualized using ECLTM Western blotting 
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detection deagents and autoradiography films (Amersham Biosciences). B-actin protein 
expression was used as a reference loading control to normalize protein expression of 
samples. 
3.5 Statistical analysis. 
Student’s t-test (paired two-tailed) and GraphPad Prism software (GraphPad Prism 
Software Inc., San Diego, CA) were used for comparisons between groups. Differences 
were considered significant at p<0.005. 
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4. RESULTS 
4.1 Synthetic glucose analogues: synthesis and screening. 
Our recent findings indicate that the activation of SGLT-1 interacts with inflammatory 
signalling and suggest a novel role as an immunological player for this glucose transporter. 
High glucose levels in vitro and in vivo loads reduction of systemic pro-inflammatory 
signals, such as TNF-α, and the induction of endogenous IL-10 production by the host’s 
immune cells. But high amounts of glucose that are necessary to induce these anti-
inflammatory effects in vivo are considered a serious limitation for therapeutic application. 
Therefore we have collaborated with a chemical team  in order to synthesize new analoge 
glucose, with high affinity versus SGLT-1. This chemical team is from Department of 
Biotecnology and Bioscience, Università degli Studi di Milano Bicocca. 
In the search for non-metabolizable glucoderivatives able to “activate” the SGLT-1 
transporter at pharmacological concentrations, the chemical researcher team  generated a 
small library of naphthyl C-glycoside and glycitol derivatives, mostly without the use of 
protecting groups. We tested in vitro anti-inflammatory activity of different coumponds 
(data not shown), among them, we have selected a synthetic SGLT-1 ligand, named 
BLF501 (fig.1), which binds to the transporter with high potency, i.e. at concentrations 5 
orders of magnitude lower than glucose.  
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Fig. 1. Synthesis and Structure of BLF501 
4.1.1 Stability studies. 
BLF501, a member of the C-glycoside class, was designed to resist glucose metabolism 
and to retain hydrolytic stability in the acidic and basic conditions found in the 
gastrointestinal tract. Stability of BLF501 in different pH conditions was tested in samples 
prepared by dissolving 2.3 mg in 550 µl of D2O and adjusting the pH to 1.2 through DCl 
addition (acidic conditions) or by dissolving 3 mg of BLF501 in 550 µl of D2O and adjusting 
the pH to 12.5 through NaOD addition (basic conditions). Both samples were kept at room 
temperature until 1H-NMR spectra were recorded at 10 min, 4.5 h and 24 h. As shown in 
Figure 2, neither sample evidenced degradation in 24 h. 
3 mg pH 12.5 (D20, NaOD)     2.3 mg pH 1.2 (D20, DCl) 
 
 
 
 
 
 
Fig. 2. 1H-NMR spectra of BLF501 at pH 12.5 and at pH 1.2. 
 
ppm (f1)
2.03.04.05.06.07.08.0
10 min
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4.1.2 BLF501 affects LPS-induced IL-8 release in intestinal epithelial cells 
Intestinal epithelial cells (IECs) express both the glucose transporter SGLT-1 and 
members of TLR family. In human and mouse IECs, TLR activation induces production of 
molecules such as the chemokines IL-815,16. We analyzed the effect of BLF501 on IL-8 
release upon LPS agonist of TLR4, in human colon carcinoma cells line HT29. 
Experiments were carried out varying the BLF501 content in HT29 medium between 50 
mg/l and 0,05 µg/l. Cells were cultured for 18h in different medium and stimulated for 6h 
with LPS (1 µg/ml). Supernatants collected after 24 h were assayed for IL-8 production. 
Ours resuts show that a significant reduction in IL-8 release was observed for all IECs 
cultured in media containing BLF501 at 50 mg/l, 5 mg/l, 50 µg/l, 5 µg/l. At 0,5 µg/l BLF501 
lose more of fifty percentuage of its anti-inflammatory activity and at 0,005 µg/l BLF501 
completely lose its activity (fig.3). 
 
Fig.3. IL-8 production upon treatment with LPS (1 μg/ml). BLF501 at concentrations from 50 mg/l 
to 0,005 µg/l.. Data are the means (±SD) of three independent experiments performed in triplicate. 
*, p < 0,001 vs LPS. 
 
In order to determine the actual involvement of SGLT-1 in the inhibitory effect of BLF501 
on IL-8 production, the assay was repeated on HT29 cells with SGLT-1 silenced through 
** ** ** ** 
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transfection of the cells with small interfering RNA (siRNA) targeting SGLT-1 mRNA. As 
shown in Fig. 4 (last column) the siRNA clearly reduced the inhibitory effect of BLF501 5 
µg/l on IL-8 production. This result proves the key role of the transporter and demonstrates 
that the biological activity of the compound is the consequence of its interaction with the 
transporter. 
 
Fig. 4. IL-8 production in untreated HT29 cells, or HT29 cells treated with siRNA alone, LPS alone, 
LPS + siRNA, LPS + BLF501, or LPS + BLAF501 + siRNA. Data are the means (±SD) of three 
independent experiments performed in triplicate. 
 
4.1.3 Protection afforded by BLF501 in LPS-induced shock in mice. 
LPS plays a key role in Gram-negative sepsis by inducing production of cytokines, which 
mediate hyperactivation of the inflammatory system, eventually leading to death by 
endotoxic shock88; i.p. administration of LPS plus GalN provides a model of endotoxic 
shock in mice89. In our recent work6 we show that oral administration of gluose o 3-OMG 
protects 100% of mice in this animal model  To evaluate the effect of BLF501 in this 
animal model, mice (5/group) were treated i.p. with LPS (250 µg/kg) and GalN (1 g/kg) or 
pretreated orally with BLF-501 1h before LPS/GaIN or left untreated. 
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The first step was to determine the effective dose of BLF501. As can be seen from fig. 5, 
BLF501 afforded protection against LPS/GalN induced shock with an ED50 of 2.5 μg/kg 
(0.05 μg/mouse). The ED100 was 25 μg/kg (0.5 μg/mouse). Of note, 25 μg/kg is a 
100,000-fold lower dose than the dose of glucose used in similar experiments, i.e. 2.5 g/kg 
(50 mg/mouse). 
 
Fig. 5 Dose-response experiment of the protection afforded by p.o. administered BLF501 in LPS-
induced shock in mice (n=5/group). 
 
To increase animal number for each group we performed a second experiment, 
administrating oraly effective dose BLF501 25 µg/kg . A group of 10 animals was treated 
only with LPS (250 µg/kg) and GalNH2 (1 g/kg); a second group of 10 mice was treated 
with LPS (250 µg/kg), GalNH2 (1 g/kg) and BLF501 (25 µg/kg) administrated orally with 
gavage; finally a control group of mice was treated only with sterile water, and another 
group treated with only BLF501 (25 µg/kg). Results are reported in figure 6. As expected, 
in the first group of mice treatment with LPS/GalNH2 induced septic shock with 100% of 
death within 36 h from the treatment, while in the group treated with LPS/GalNH2 and 
BLF501 a survival of 100% of the mice along with behavior comparable to untreated 
55 
 
animals was observed. This result seems to confirm the great potentialities of BLF501 in 
the inhibition of bacteria-induced inflammatory processes and in its use as a life-saving 
treatment. 
 
 
Fig. 6. Protection afforded by BLF501 25 µg/kg in LPS-induced shock in mice. Untr = untreated; 
LPSGalN = Mice treated with LPS/GalN alone; LPSGalNBLF501 = Mice treated with LPS/GalN + 
BLF501; BLF501 = Mice treated with BLF501 alone (n=10/group). 
 
We performe a second experiment to determine inflammatory cytokine levels in plasma 
semple with BLF501 25 µg/kg. Figure 7 shows that BLF501, similarly to glucose, inhibits in 
this setting the production of the inflammatory cytokine IL-12 and induces the production of 
the anti-inflammatory cytokine IL-10. BLF501 alone, like glucose, is inactive in modulating 
serum cytokine levels. 
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B 
Fig. 7. Serum levels of IL-12 (A) and IL-10 (B) in untreated mice, or mice treated with LPS/GalN 
alone, BLF501 alone or LPS/GalN+BLF501. Untr = untreated; LPS/GalN = Mice treated with 
LPS/GalN alone; LPS/GalN BLF501 = Mice treated with LPS/GalN + BLF501; BLF501 = mice 
treated with BLF501 alone. Values represent the mean of 10 animals/group. Data are the means 
(±SD). *, p < 0,001 vs LPS/GalN. 
** 
** 
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4.2 SGLT-1 a new therapeutic target for epithelial barrier 
function.  
4.2.1 SGLT-1 activation by BLF-501 5 µg/l effects on permeability of Caco-2 
monolayer against inflammatory stimuli (INF-γ and TNF-α) and “chemical-DSS” 
damage. 
We showed6 that SGLT-1 activation, by high doses of oral glucose (2.5 g/kg), leads to the 
protection of the intestinal epithelium in a LPS-induced enterocolitis mouse model, and in 
particular Ussing Chamber analysis in order to valuate intestinal resistence, showed that 
the intestinal permeability remains similar to the one of untreated mice. This suggests that 
the intestinal epithelial barrier function is protected by damages associated to this 
inflammatory state, when SGLT-1 is activated. Complexities of the in vivo system make it 
difficult to determine effects of BLF501 administration on intestinal epithelial barrier.To 
determine if BLF501 can signal directly to intestinal epithelial cells we have used two 
inflammatory in vitro models, that cause dysfunction of the epithelial monolayer. Differents 
works have established that INF-γ and TNF-α are both required to decrease barrier 
function in cultured monolayer of intestinal epithelial Caco2 cells90. We cultured Caco2 
cells on transwell filters, placed in p24, plates reaching monolayer stadium. We treated 
Caco-2 monolayer transwell with INF-γ and TNF-α and we have evaluated the permeability 
activity of Caco-2 monolayer by measuring the paracellular penetration amount of FITC-
DEXTRAN (FD-3) across Caco-2 monolayer. The involvement of the paracellular pathway 
was confirmed by increased flux of the FD 3 paracellular marker.  Addition of INF-γ and 
TNF-α to the lumen side of Caco-2 cells monolayers grown on permeable supports led to 
an immediate FD-3 permeability increased. The flux of FD-3 of INF-γ/TNF-α-treated Caco-
2 cells had increased 20 ±5 fold, from 23,55 ±14 pmole/cm2/h (control) to 174 ±22 
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pmole/cm2/h (treatment)  The addition of BLF501 5 µg/l, the lower efficace anti-
inflammatory (as shown before) concentration, in apical medium significantly prevented an 
increased in permeability to FD-3 induced by INF-γ and TNF-α (fig 8). The flux of FD-3 of 
BLF-501 and INF-γ/TNF-α-treated Caco-2 cells  is 31±16 pmole/cm2/h comparable to 
untreated monolayer. BLF-501 50 µg/l prevent paracellular flux alteration induced by 
inflammatory stimuli. 
 
Fig 8 BLF501 protection against IFN- γ and TNF- α-damage in barrier function. Caco-2 monolayers 
were incubated with the indicated cytokine (IFN-γ 10 ng/ml, TNF-α 25 ng/ml) added to media in the 
basal chamber. Conditions were no cytokines (untr). Monolayers were assayed for permeability to 
3kD fluorescein isothiocyanate-dextran. Paracellular permeability was increased only in cells 
exposed to IFN-γ followed by TNF-α without BLF. Data are the means (±SD) of two experiment 
performed in triplicate. *, p < 0,001 vs INF/TNF. 
** 
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4.2.2 BLF501-mediated barrier functionality protection is associated to a 
morphological conservation of two TJ proteins. 
Modulation of barrier/permeability properties is often mirrored by changes in specific TJ 
protein components. We have performed a series of in vitro experiments of 
immunofluorescence staining to analyze the effects of SGLT-1 activation by BLF501 on 
tight junctions protection. We performed immunofluorescence staining for occludin and 
ZO-1 in Caco2 monolayers, to analyze if BLF501 is able to protect from TNF-α- and INF-γ-
induced damage.  
In control, untreated monolayers, ZO-1 and occludin were predominantly localized to the 
apical lateral membrane, producing a characteristic “honeycomb” pattern consistent with 
their distribution in TJs. Addition of TNF-α- and INF-γ to medium of Caco-2 cells for 24 h 
clear differences in the staining patterns were noted. For occludin the staining became 
more punctuate and less intense consistent with a loss of protein form the cell.  For ZO-1 
the staining becomes more disordered and irregular. INF-γ and TNFα stimulated Caco-2 
monolayers treated with BLF-501 (5 µg/l) show a ZO-1 and occludn localization similar to 
control monolayer (fig. 9 and 10). 
 
Fig.9 Staining for occludin in Caco-2 monolayer. (A) Untreated. (B) INF-γ and TNF-α treatment. (C) 
INF-γ snd TNF-α plus BLF501 5µl/l. In red occludin staining and in blue DAPI. These images are 
representative of 5 slide for each treatment. Medium added with only BLF501 µl is comparable to 
untreated monolayer. Bar 10 µm 
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Fig.10 Staining for ZO-1 in Caco-2 monolayer. (A) Untreated. (B) INF-γ and TNF-α treatment. (C) 
INF-γ snd TNF-α plus BLF501 5µl/l. In red occludin staining and in blue DAPI. These images are 
rappresentative of 5 slide for each treatment. Medium added with only BLF501 µl is comparable to 
untreated monolayer. Bar 10 µm.  
 Moreover we performed immunofluorescence staining for occludin and ZO-1 in Caco2 
monolayers, to analyze if BLF501 is able to protect from DSS-induced damage. In cells 
treated with DSS 5% for 24 h clear differences to untreated cells in the staining patterns 
were noted. For occludin and ZO-1 staining became irregular in several zone of DSS 
stimulated Caco-2 monolayer. Caco-2 monolayers treated with DSS and BLF-501 (5 µg/l) 
have a pattern of ZO-1 and occludin localization similar to control (fig. 12 and 13).  
 
 
Fig.11 Staining for ZO-1 in Caco-2 monolayer. (A) Untreated. (B) DSS 5% treatment. (C) DSS 5% 
plus BLF501 5µl/l. In red ZO-1 staining and in blue DAPI. These images are rappresentative of 5 
slide for each treatment. Medium added with only BLF501 µl is comparable to untreated 
monolayer. 
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Fig.12 Staining for occludin in Caco-2 monolayer. (A) Untreated. (B) DSS 5% treatment. (C) DSS 
5% plus BLF501 5µl/l. In red ZO-1 staining and in blue DAPI. These images are rappresentative of 
5 slide for each treatment. Medium added with only BLF501 µl is comparable to untreated 
monolayer 
This suggest that SGLT-1 activation by BLF501 induce protection of barrier function that in 
this in vitro model is directly distrupted by DSS. BLF-501 protects TJ indirectly inhibiting 
inflammatory response and directly  tight junction protein. 
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4.2.3 BLF501 protection against inflammatory bowel disease in vivo 
In vitro results lead us to hypothesize that SGLT-1 may be an important target in bowel 
inflammatory disease, where increased permeability is not simply an epiphenomenon but 
rather is an important aetiological event. We tested BLF501’s activity in a chemically 
induced mouse model of acute and chronic intestinal inflammation. Different models of 
experimental IBD have been developed to investigate pathogenesis and to test efficacy of 
therapies. We have chosen dextran sodium sulphate (DSS)-induced colitis for its simplicity 
and reproducibility of the colonic lesions. Moreover, DSS polymers in the drinking water 
are directly toxic to the gut epithelial cells, affecting firstly the integrity of the mucosal 
barrier and then stimulating local inflammation as the secondary phenomenon 91. For this 
reason we want to improve BLF.501 activity in intestinal barrier protection, which is 
thought to be the initial inciting event in many intestinal disorders, including IBD. 
 
Oral ingestion of glucose  and BLF501 protects mice from DSS-induce diarrhoea. 
A DSS concentration of 2% (w/v) in the drinking water for 7 days induces strong colitis92. 
To evaluate the effects of  glucose and BLF501 in this model, mice (10/group) were 
treated in the drinking water for 7 days with DSS 2% concomitantly or not with oral 
administration of BLF-501 (250 or 25 µg/kg) or glucose 2,5 g/kg once per day in the last 
four days (as described in materials and methods). DSS intake did not differ in different 
groups of mice. 
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In the following scheme animal groups (n = 10): 
Aniaml group Treatment 
1 Untreated 
2 DSS 2% only 
3 DSS 2% + Glucose 2,5 g/kg 
4 DSS 2% + BLF501 250 µg/kg 
5 DSS 2% + BLF501 25 µg/kg 
6 DSS 2% + BLF501 2,5 µg/kg 
7 Glucose 2,5 g/kg only 
8 BLF501 250 µg/kg 
9 BLF501 25 µg/kg 
10 DSS 2% + physiological solution 
 
Colitis in the DSS model is usually strongly associated with wasting disease. 
Determination of weight every day to get a rough idea of colitis severity and is often 
indicative of differences in colitis development between experimental groups. As shown in 
fig 14 at 8 day the body weight significantly decreased in DSS group compared to control 
mice. The oral treatment with BLF 501 at doses of 250 µg/kg and 25 µg/kg recover weight 
loss DSS-induced; the 2,5 µg/kg dose appared to be ineffective.  
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Fig.14 Body weight loss. Gramme of body weight lost after different treatments versus control 
group. Values represent the mean of 10 animals/group. Data are the means (±SD). **, p < 0,001 vs 
DSS. 
 
The DSS-demages are generally located in the distal colon, whose length decreases as 
the disease develops. Colon mean lenght of mice group treated only with DSS decrease of 
32% compared to untreated group (fig 15 B). Glucose 2,5 g/kg or BLF501 at 250 µg/kg 
and 25 µg/kg oral treatment of mice significantly reduced colonic shortering induced by 
DSS. Group of mice treated with BLF501 2,5 µg/kg and DSS shows colon lenght similar to 
DSS group. 
About body weight and colon lenght results load us to consider 25 µg/kg like the minum 
effective dose of our analogue glucose in this animal model. 
** ** 
** 
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Fig. 15 
(A) Colon rapresentative photos. Colon of mice treated with glucose or BLF501 250 µg/kg or 
BLF501 25 µg/kg only are similar to untreated group. BLF501 2,5 µg/kg group show colon similar 
to animals treated only with DSS  (B) Colon length. Values represent the mean of 10 
animals/group. Data are the means (±SD). **, p < 0,01 vs DSS. 
 
** 
** ** 
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After evaluation of colon lenght, colitis level of different group was scored using a standard 
parameter stool consistence. In fig. 15 A the colon photos show that DSS animals group 
have very soft stools with a 1,9 mean score, whereas untrated group shows normal stools 
with mean score 0 (fig. 16). Stool consistence of animal treated with DSS and Glucose 2,5 
g/kg or BLF501 250 or 25 µg/kg is confrontable to untreated group. These results shown 
that oral treatment with glucose or BLF 250 or 25 µg/kg inihibit water loss, mantaining 
normal stool consistence. 
 
 
Fig 16 
Scoring system for the comparative analysis of stool consistence. Values represent the mean of 10 
animals/group. Data are the means (±SD). **, p < 0,001 vs DSS. 
 
The most important damage DSS-induced is characterized by changes in colon mucosa, 
that show loss of crypts and reduction of globet cells, signs of surface epithelial 
regeneration, focal ulcerations, infiltration of inflammatory cells into the mucosa, and 
edema in the sub-mucosa. Histopathological analysis using hematoxylin-eosin staining  of 
colon section shows that drinking water added with DSS 2% for 7 days induces crypt 
demage, ulceration, and infiltration of inflammatory cells in the distal colon. An histological 
** 
** 
** 
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colitis score was calculated for 10 slide for each mouse of different groups and in fig. 18 
we have reported the mean score. Score increasing has associated with inflammation 
develop (mean score of DSS group 3,5 vs untreated 0). Scoring system of colon section of 
DSS treated group plus glucose or BLF501 250 or 25 µg/kg shows protective role of 
SGLT1 in this animal model of acute colitis. 
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Fig 17 (A) Rapresentative colonic H&E section from mice receiving water without DSS . a) Lamina 
mucosa; b)Lamina submucosa; c)Circular and longitudinal mussle. In magnification arrow shows 
colon crypte with normal morphology and black arrowhead indicates globet cells. (B) Colon 
histology from DSS-treated group. DSS induces thickening of the colon wall, globet cells and crypt 
loss in large areas (in magnification arrow). Infiltration reaching the lamina submucosa (withe 
arrow). (C) Representative colon section of glucose 2,5 g/kg treatment in acute colitis. Normal 
morphology with low level of inflammation (D) H&E of BLF501 250 µg/kg and (E) BLF501 25 µg/kg, 
histologically comparable with control group. Bar 50 µm 
D 
E 
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Fig. 18 Histological scores of the colon section stained with H&E. Results are representative of 10 
section for five animal for eachh group. DSS mean score shows high level of inflammation with 
transmurall leukocite infiltration and loss of globet cells. Glucose 2,5 g/kg or BLF501 250 and 25 
µg/kg oral treatment prevents and protects from mucosal demage DSS-induced. 
 
DSS is directly toxic to gut epithelial cells of mucosal epithelium and induces a alteration of 
the mucosal barrier, with increase of antigens from colon lumen to lamina propria. In this 
animal model intestinall permeability alteration is the first step in colitis etiology/onset. 
Previous data have already described that an increased colon permeability is associated 
with colitis development after administration of DSS 93-95. Ussing Chamber analysis of the 
colon of DSS-treated mice presented very low transmembrane resistance (25 ± 2,24 Ωcm2 
vs 53.4 ±2,73  Ωcm2 for untreated mice), indicating an increased permeability, whereas in 
mice group treated with DSS and oral administration of glucose 2,5 g/kg and BLF501 250 
and 25 µg/kg the transmembrane resistance remained similar to untreated mice 
(respectively 49,6 ± 1,52 Ω cm 2 or 50,4 ± 1,52 or 50,2 ± 1,2 vs 53.4 ±2,73 Ω cm2 in 
untreated mice). This suggests that the increase of colon permeability DSS-induced is 
recovery and protects by glucose and/or BLF-501 oral administration. 
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Fig 19. Colon resistence. Values represent the mean of 5 animals/group. Data are the means 
(±SD). **, p < 0,001 vs DSS. 
 
This intestinal inflammation  mouse model is associated with local increases in cytokines 
and chemokines. To test whether the DSS-induced acute colitis we observed in the 
BLF501-treated mice was associated with decreased inflammatory cytokines production in 
the intestinal mucosa. We have evaluated the level of TNF-α and IL-12. At 8 days after 
colitis induction, the levels of these cytokines increased significantly in the mucosa of the 
DSS-treated mice compared with control mice. Dextran sulphate sodium-induced increase 
in TNF-α and IL-12 mucosa levels were significantly suppressed by the administration of 
BLF-501 (fig.20 A and B). There were no significant differences in these cytokines levels 
between the DSS mice after given BLF-501 and the control mice. 
** ** ** 
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Fig. 20 Colonic secretion of TNF-α (A) and IL-12 (B). DSS-induced chronic colitis loads to a 
significant increase in colonic secretion of TNF-α and IL-12, wich was redeced by oraly 
administration of BLF501 25 µg/kg. Values represent the mean of 5 animals/group. Data are the 
means (±SD). *, p < 0,005 vs DSS. 
 
Recently, IL-10 was introduced as a potential new anti-inflammatory therapy in Crohn’s 
disease, but IL-10 treatment did not result in significantly higher remission rates or clinical 
improvement. The explanations for the failure of this therapeutic strategy might be that the 
* 
* 
* 
* 
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administered dose of IL-10 in the clinical trials, and thus the ultimate local IL-10 
concentration in the intestine, might be too low to result in down-regulation of 
inflammation96. In our previous study6, we have demonstrated that the protective effect of 
the activation of SGLT-1 by high doses of oral glucose (2.5 g/kg) in septic shock animal 
model depends from an increase of the anti-inflammatory cytokine IL-10. We evaluated by 
ELISA IL-10 levels in colon colture and our data (fig. 21) show that in this colitis animal 
model oral administration of glucose or BLF501 increase this anti-inflammatory cytokine. 
 
Fig 21 IL-10 levels in colonic colture DSS-induced chronic colitis loads to a insignificant increase in 
colonic secretion of IL-10, wich was significantly increased by oraly administration of glucose or 
BLF 250 and 25 µg/kg. Data are the means (±SD). *, p < 0,005 vs DSS. 
 
BLF-501 oral administration protects against chemically-induced mouse model of chronic 
intestinal inflammation.  
SGLT-1.activation by BLF501 protects against chemically-induced acute colitis mouse 
model, with important role in recovery of epithelial barrier intestinal barrier function. 
Several data in letterature show that in different animal model of Crohn disease70,71,79 an 
* 
* 
* 
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increased intestinal permeability has been shown before inflammation expression and the 
reversal of this defect can attenuate the disease. 
The administration of DSS at a concentration of 2% in the drinking water for three cycles is 
chemically-induced mouse model of chronic intestinal inflammation. To evaluate the effect 
of BLF-501 in this colitis model, we have performed five animal groups of 5 mice/group. 
Four groups received three cycles of treatment with DSS. Each cycle consists of 2% DSS 
dissolved in the drinking water for 7 days, followed by a 14 days interval with normal water 
administration. Ten days after completion of the last DSS cycle, one group of mice 
received 25 µg/kg BLF501 per os, 4 times a week, for 3 consecutive weeks; another group 
of mice received 25 µg/kg BLF501 per os 4 times a week, for 2 consecutive weeks; the 
third group of mice received 25 µg/kg BLF501 per os 4 times a week, for 1 week only; the 
fourth group of mice received only three cycles of treatment with DSS, the last group of 
animals (control group) received normal drinking water only, during the whole time of the 
experiment. 
Macroscopical evaluation of BLF501 25 µg action in chronic colitis. 
The length of the colon decresed as the disease developed. After chronic colitis induction, 
in DSS administered mice the colon length was significantly shorter than control mice. A 
significant decrese in the shortening of the colon length was observed in mice that had 
received BLF-501 almost for 3 week compared with DSS-administered mice (fig. 22). 
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Fig 22 Distal colon length. Values represent the mean of 5 animals/group. Data are the means 
(±SD). *, p < 0,005 vs DSS. 
,Moreover, chronic colitis level of different groups was scored using a standard parameter 
stool consistence. Fig. 23 show that DSS-treated group has soft stools with a 1,3 mean 
score, whereas untrated group shows normal stools with mean score 0. BLF501 treatment 
for 3 week restores completly stool consistence. 
 
Fig 23 Scoring system for the comparative analysis of stool consistence. Values represent the 
mean of 5 animals/group. Data are the means (±SD). *, p < 0,005 vs DSS.  
* 
* 
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Barrier morphology and function of colon mucosal is restored in BLF-501-treated mice 
Histological examination of colon tissue from DSS-treated mice showed, upon 
hematoxilin/eosin staining, prominent signs of inflammation with scattered, infiltrating 
mononuclear cells and thickening of the intestinal wall. On the other hand, very mild signs 
of inflammation were seen in tissue samples from animals treated with DSS and BLF501 
25 µg/kg administrated for 3 week. 
 
A 
B 
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Fig 24 (A) Rapresentative colonic H&E section from mice receiving water without DSS . In 
magnification colon cryptes with normal morphology. (B) Colon histology from DSS-treated group. 
DSS induces thickening of the colon wall and infiltration reaching the lamina submucosa (in 
magnification). (C) Representative colon section of BLF501 25 µg/kg histologically comparable 
with control group. Bar 50µm (D) Histological scores of the colon section stained with H&E. Results 
are representative of 10 sections for each animal of different groups (n=5). DSS mean score 
shows high level of inflammation with transmurall leukocite infiltration. Oral administration of 
BLF501 25 µg/kg for 3 week restores mucosal demage DSS-induced. Data are the means (±SD). 
*, p < 0,005 vs DSS. 
 
The intestinal epithelial barrier function is demaged in chronic inflammation, manifested by 
an increase in intestinal epithelial permeability. Indices of permeability typically are 
transepithelial resistence (TER) obtained from formalized assays using Ussing chamber. 
We analyzed the colon permeability in order to determine if BLF501 is able to restore the 
electrophysiological barrier function. Segments of colon were mounted in Ussing 
chambers and trans-epithelial electrical potential difference (mV) across the mucosal 
membrane and the short-circuit current (µAmp) were measured directly, while the 
transmembrane resistance was calculated as ohm x cm2, as determined using Ohm's law. 
As shown in fig. 25 DSS treatment significantly reduced the barrier function of colon tissue, 
because loads to increase in TER, while BLF-501 oral administration restors transepithelial 
resistence. 
* 
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Fig.25 Colon resistence. Data are the means (±SD). *, p < 0,005 vs DSS.  
 
Since epithelial tight junctions regulate paracellular permeability94 and DSS induced 
chronic colitis is associated with increased intestinal permeability with decreased 
expression of occludin and ZO-1 protein. we examined the effect of BLF501 on 
morphological organization of these tight junction protein. 
In colon of control mice, the protein occludin and ZO-1 were precisely localized to the 
epithelial TJ. Immunofluorescence detection of these protein (fig. 26 A, E and 27 A) show 
regular series of bright red lines at the apical aspect of cell junctions. In contrast the 
immunofluorescence signals of occludin and ZO-1 were disrupted and irregularly 
distributed in DSS-induced colitis (fig. 26 B and 27 B), while the signals appeared as a 
typical reticular pattern by the oral administration of BLF501, without any morphological 
alteration (fig.26 C and 24 C). 
These findings suggest that the recovery of mucosal impairment in DSS-induced chronic colitis.due 
to oral treatment with BLF501 is associated with the restoration of the tight junction protein 
occludin and ZO.1. 
*
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Fig 26 Immunofluorescence ZO-1 detection Confocal (A-D) and Video Confocal image (E-H). A 
and E) Colon section of untreated mice, ZO-1 detection (magnification 60X). ZO-1 is stained red is 
exclusively localized at the apical junctional complex both at the surface and in the crypts. B and F) 
In DSS-treated animals, a substantial redistribution of ZO-1 away from tight junctions occurred. 
This change was manifested by discontinuities in membrane staining, in some areas there was 
complete loss of staining. Withe arrows show crypt with reduced ZO-1 staining and loss of crypt 
morphology. C and G) Colon section of chronic DSS and BLF501 administration show a 
continuous and intense staining pattern similar to healthy controls. Images are representative for 5 
colon section for each animals/group. Bar 25 µm 
  
 
Fig. 27  Immunofluorescence for occludin. Representative images for occludin are shown for the 3 
groups. The tight junction proteins are stained red, and nuclei are blue. A) Occludin exclusively 
localizes at the apical tight junction, and an intense apical fluorescence band is found in healthy 
animals. The apical staining of occludin is strongly reduced in DSS treated animals. C) In BLF501-
treated animals, apical staining is preserved (arrows). Images are representative for 10 slide for 
each animal (n=5).  
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Fig.28 Graphic representation of percentage of crypts non DSS-demaged in colon section stained 
for occludin and ZO-1 tight junction proteins. Values represent the mean of 10 slide for each 
animal (5 animals/group) Data are mean (±DS) **, p < 0,001 vs DSS.
** 
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4.3 SGLT-1 a new therapeutic target in lung inflammatory 
disease 
4.3.1 Engagement of SGLT-1 inhibits the response of human pneumocytes to LPS. 
Western blot analysis (fig. 29) showed that A549 human pneumocytes express SGLT-1, 
consistent with findings in rat type II pneumocytes (97), while 16-HBE human bronchial 
epithelial did not. 
 
Fig.29 Western blot analysis of SGLT-1 expression in A549 human pneumocytes, 16-HBE human 
bronchial epithelial cells, HUH 7 human liver hepatoma cells (negative control) and CaCo-2 human 
colorectal carcinoma epithelial cells (positive control). B-actin expression was used as a reference 
loading control (data not shown). 
 
4.3.2 BLF501 inhibits LPS-induced interleukin IL-8 production in human 
pneumocytes A549 cells at 100,000-fold lower concentrations than D-glucose.  
To determine whether D-glucose and the synthetic D-glucose analogue BLF501 inhibit 
LPS-induced IL-8 production, A549 cells were cultured for 18 h in the presence of a D-
glucose concentration 5-fold higher than in normal medium (“high D-glucose” medium, 
27.78 mM), or in the presence of 50 µg/L of BLF501 (11.36x10-7 mM), and subsequently 
stimulated for 6 h with LPS from Pseudomonas aeruginosa (100 µg/ml). Both D-glucose 
and BLF501 suppressed IL-8 production in LPS-stimulated A549 cells to levels similar to 
those of unstimulated cells (fig.30 A), while the same experiments using 16-HBE human 
bronchial epithelial cells revealed no inhibition of LPS-induced IL-8 production by either D-
glucose or BLF501 (fig. 30B). The involvement of SGLT-1 in glucose- or BLF501-induced 
inhibition of LPS-induced responses in A549 cells was confirmed in experiments using 
SGLT-1 mRNA-specific small interfering RNA (siRNA) to silence SGLT-1 expression, 
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resulting in the abrogation of the inhibitory effects of D-glucose and BLF501 on LPS-
induced IL-8 production (fig.30 A). 
A B 
Fig.30 A) IL-8 levels in colture medium A549 after LPS pseudomonas treatment. Glucose or 
BLF501 B) IL-8 levels in colture medium 16-HBE 
 
These results indicate the essential role of SGLT-1 in glucose- and BLF501-induced 
modulation of LPS-driven cytokine responses in human pneumocytes. 
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4.3.3 Protective anti-inflammatory effects induced by BLF501 engagement of SGLT-
1 in lung after aerosol administration of LPS. 
Immunofluorescence analysis of lung samples showed that pneumocytes expressed 
SGLT-1, while bronchial epithelium was not stained (fig. 31), consistent with the 
observations in cell lines. 
 
Fig 31 SGLT-1 expression in normal murine lung. Expression of SGLT-1 was detected by 
immunofluorescence analysis on normal alveolar pneumocytes (a), but not on normal bronchial 
epithelial cells (b), by incubation of lung sections with a polyclonal anti-SGLT-1 antibody (Zymed 
Laboratories), diluted 1:1000 in PBS, for 1 h at room temperature, followed by addition of goat anti-
rabbit antibody Alexa 488, diluted 1:200 in PBS and 3% BSA, for 30 min at room temperature. 
Bars: 50 µm. 
We then assessed whether SGLT-1 engagement exerted anti-inflammatory effects in an in 
vivo model of LPS-induced lung injury in experiments using only BLF501, since the 
reagent was designed and synthesized to act as a D-glucose agonist on SGLT-1 and the 
in vitro results confirmed this assumption. Thus, groups of mice (n=5/group) received 
BLF501 via aerosol at a dose of 266 ng/ml (total of 3 ml of administered solution), based 
on preliminary dose-response experiments (fig 32), or an aerosol solution containing 3 
mg/ml LPS (3 ml), or both (at the above dosage but in 3 ml total) daily for 5 consecutive 
days. At the end of the treatment period, blood and lung samples were collected for 
analysis.  
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Fig 32 Dose-response of aerosol LPS-exposed mice to BLF501. Mice were exposed to LPS as 
described in Methods and additionally treated or not with aerosolized BLF501 in decreasing 
concentrations from 0.11 mM to 11 pM. The graph shows that the highest anti-inflammatory 
activity, evaluated based on serum KC levels, was obtained using BLF501 at a dosage of 1.1 µM. 
Data are mean ±S.D. (n=3/group).* p < 0,005. 
Fig. 33 shows that lungs of mice exposed to LPS showed marked inflammatory alterations, 
characterized by the presence of alveolar haemorrhage and massive extravasation into 
the alveolar spaces of both mono- and polymorphonuclear leukocytes, aggregated in 
clusters, and numerous eosinophils and neutrophils. Some neutrophils were also present 
in bronchial spaces, associated with many macrophages. Massive alterations involved the 
bronchial epithelium, with areas of proliferation with rare superficial mitosis and alterations 
of the nuclei. By contrast, lung parenchyma of mice concomitantly treated with BLF501 
and LPS revealed an almost physiological morphology, with only rare eosinophils present 
in alveolar septi and with pervious bronchial lumens.  Immunohistochemical analysis of 
lung tissue for Inter-Cellular Adhesion Molecule 1 (ICAM-1) and caveolin showed that 
expression of both of these inflammation markers was increased in mice treated with LPS 
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alone, while expression in mice treated with BLF501 and LPS was comparable to that in 
controls.  
 
Fig. 33. Aerosolized BLF501 protects lung from injury after aerosol administration of LPS. A) 
Histological examination of lung samples from mice exposed to LPS, showing marked 
inflammatory alterations characterized by massive extravasation of leukocytes aggregated in 
clusters into the alveolar spaces and areas of proliferation of the bronchial epithelium (arrows). 
Lung samples of mice concomitantly treated with BLF501 and LPS showed no alterations of lung 
parenchyma. Bars: 50 µm. B) and C) Immunohistochemical analysis of lung samples using anti-
A 
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ICAM-1 (c) and anti-caveolin (d) antibodies, respectively, revealing increased expression of ICAM-
1 and caveolin in mice treated with LPS alone, but expression comparable to that of controls 
(UNTR) in mice treated with BLF501 and LPS. Bars: 50 µm. 
Analysis of the bronchoalveolar lavage fluid (BALF) revealed a massive increase in total 
cell numbers, with neutrophils and macrophages representing the majority of cells, in mice 
treated with LPS only, while alveolar spaces of LPS plus BLF501-treated mice showed cell 
numbers comparable to those in controls (Table 1). 
 Untreated BLF501 LPS BLF501+LPS 
Neutrophils 134/ml ± 15 128/ml ± 18 3450/ml ± 332 122/ml ± 20 
Macrophages 32/ml ± 7 30/ml ± 8 233/ml ± 32 34/ml ± 14 
 
Table 1. Evaluation of neutrophils and macrophages infiltrate in bronchoalveolar lavage fluid 
(BALF) from untreated and LPS-, BLF501-, LPS plus BLF501-treated mice (5 mice/group). Cells 
from BALF were fixed in formalin plus sucrose solution and deposited on glass slides by 
cytocentrifugation. Differential counts were performed on Giemsa-stained cytospins. Data are 
mean numbers of cells/ml BALF ± S.D. 
Analysis of the fluid phase of BALFs for NO, a marker of cellular stress and damage98, 
revealed high NO levels in LPS-treated mice,  but significantly lower levels in mice treated 
concomitantly with BLF501 (fig. 34). Together, these data strongly suggest that BLF501 
leads to marked anti-inflammatory effects in vivo. 
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Fig. 34 NO levels in BLF fluids. BLF501 reduced NO levels, a marker of cellular stress and 
demage, induced by LPS administration. 
 
4.3.4 Anti-inflammatory effects of BLF501 in an OVA-induced model of allergic 
asthma. 
To assess whether BLF501 might inhibit other lung  inflammatory conditions such as 
allergic asthma, we used a murine model of OVA-induced asthma, which leads to 
pulmonary injury characterized by intense inflammation with marked eosinophilic cellular 
infiltration and high levels of systemic TNF-α, IL-4 and IL-5 levels99. Asthma was induced 
in two groups of mice (n=5/group) by i.p. immunization with 100 µg OVA and 500 µg of 
aluminum hydroxide, followed by an aerosol of 5% (wt/vol) OVA; one of the groups 
received concomitant aerosol administration of BLF501 (266 ng/ml, 3 ml), while a third 
group remained untreated. Histological examination of lungs from OVA-treated mice 
showed the presence of a marked cellular infiltrate (fig. 35), with inflammatory cells 
aggregated all around the small blood arteries and apparently in strict contact with the 
external wall of the vessel, with no evidence of infiltration in the muscular tunica. An 
inflammatory infiltrate consisting of lymphocytes and eosinophils was also present along 
the external bronchial wall, while the lumen of mid-dimensional bronchi was characterized 
by mucus, containing several erythrocytes. A marked inflammatory infiltrate was also 
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observed in the alveolar septi, while bronchial cylindrical epithelial cells showed significant 
hyperproliferation.  By contrast, mice concomitantly treated with BLF501 presented a 
conserved lung architecture (fig. 35), with no inflammatory infiltrate in the vascular or in the 
bronchial region and no mucous secretory product in the bronchial lumen. Analysis of  
BALFs showed a strong increase in eosinophil numbers in the lung of OVA-treated mice 
(4058±121 cells/ml), consistent with the induction of allergic asthma, while mice treated 
with BLF501 and OVA showed significantly fewer eosinophils in the alveolar spaces 
(142±27 cells/ml, p = 3.3x10-7vs. OVA), with numbers comparable to those of untreated 
mice (139±22 cells/ml). 
 
Fig. 35. Anti-inflammatory effect of aerosolized BLF501 in an OVA-induced model of allergic 
asthma. Histological examination of lungs of OVA-treated mice, revealing cell aggregates grouped 
around the small blood arteries, in strict contact with the vessel walls (thin arrows); mid-
dimensional bronchi are characterized by the presence of mucus (thin arrow) and epithelial 
hyperproliferation (thick arrow). Mice concomitantly treated with BLF501 plus OVA showed no 
alterations of lung parenchyma. Bars: 50 µm. 
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A hallmark of inflammatory damage to the lung is the development of high-permeability 
edema, characterized by a high protein content in the exudate. Indeed, the protein 
concentration in BALFs from lungs of mice exposed to OVA was very high (0.727±0.026 
mg/ml). By contrast, protein concentration in BALFs from mice treated with OVA and 
BLF501 was significantly lower (0.389±0.033 mg/ml, p = 1.3x10-4 vs. OVA) and 
comparable to that of untreated controls (0.375±0.036 mg/ml). NO levels in BALFs of 
OVA-treated mice were 19.2±1.1 µmol/ml, but 3.3±0.6 µmol/ml upon concomitant 
administration of BLF501 (p = 6.6x10-6vs. OVA), similar to those in untreated mice 
(2.6±0.4 µmol/ml). 
Levels of  IL-5 and IL-4, prototypical cytokines of allergic asthma, were elevated in sera 
(Fig. 36 a and b) and BALF (data not shown) from OVA- but not from BLF501 plus OVA-
treated mice, whereas levels of the anti-inflammatory cytokine IL-10 were greatly 
increased in sera of mice receiving BLF501 plus OVA but similar in controls and in mice 
treated with OVA alone; no IL-10 production was observed in mice treated with BLF501 
alone (Fig. 36 d). 
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** 
** 
91 
 
C D 
 
Fig. 36. Anti-inflammatory effect of aerosolized BLF501 in an OVA-induced model of allergic 
asthma. A-D) Levels of IL-4, IL-5, IL-10, and anti-OVA IgE, respectively, in sera of untreated mice 
(UNTR) or OVA-, BLF501- or OVA plus BLF501-treated mice. Data are mean ± S.D. (n=5/group). 
**p <0,001.vs OVA. 
 
Analysis of serum Immunoglobulin E (IgE) levels, which are increased in airway 
inflammation in asthma, in mice treated with aerosolized OVA, with or without BLF501 
administration, revealed significantly increased levels of anti-OVA IgE in asthmatic mice 
compared with those of control mice, while administration of BLF501 led to a significant 
decrease in these specific IgE levels (Fig. 36c). 
Together, these results demonstrate that BLF501 exerts potent anti-inflammatory effects in 
an animal model of allergic asthma. 
 
4.3.5 Orally administered BLF501 inhibits OVA-induced lung inflammation. 
We previously showed that engagement of intestinal epithelial cells SGLT-1 by orally 
administered glucose induces systemic production of protective anti-inflammatory 
cytokines6. To determine whether the anti-inflammatory effects of BLF501 might also be 
observed upon oral administration, mice receiving OVA were orally treated or not with 
** 
** 
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BLF501 (25 µg/kg), and serum, BALF and lung samples collected at the end of treatments 
were analyzed as those for mice treated with aerosolized BLF501. The results with respect 
to eosinophilic infiltrate, serum and BALF protein content, and cytokine and anti-OVA IgE 
levels (Fig. 37 a and b) were comparable to those obtained with aerosolized BLF501. By 
contrast,  no protection was observed after intravenous BLF501 administration (data not 
shown). 
Based on our previous finding in liver inflammation conditions that SGLT-1 activation is 
efficacious in triggering an anti-inflammatory activity only in the presence of a danger 
signal7, we focused on identifying the danger signal that might be involved in the protection 
in the asthma model. In many lung diseases, including chronic bronchitis, chronic 
obstructive pulmonary disease, acute lung injury, acute respiratory distress syndrome and 
asthma, Tumor Necrosis Factor (TNF)-α plays a major role 100. To test whether TNF-α 
might constitute the major danger signal in the asthma model, we monitored serum levels 
of this cytokine at various time-points during 1 month in OVA-treated and OVA plus orally 
BLF501-treated mice (Fig. 37c). Sera of mice treated only with OVA presented two peaks 
of TNF-α on the 1st and 7th day of treatment, corresponding to the two sensitizations with 
OVA and aluminum hydroxide; levels remained constant at about 100 pg/ml and increased 
again from the 12th day during the 5 days of OVA aerosol administration, reaching levels 
of about 230 pg/ml until day 22, when TNF-α levels decreased again but only to 80-200 
pg/ml.  While sera of mice concomitantly treated with OVA and oral BLF501 both during 
the sensitization phase and the challenge phase presented peak levels of TNF-α at the 
same time points as the OVA-only group, levels were consistently much lower than in the 
OVA-only group (Fig. 37c). Thus, TNF-α is produced even in the presence BLF501 
treatment. 
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To investigate the role of TNF-α in the effects of  BLF501 on OVA-induced asthma, we 
examined the lung morphology and serum/BALF cytokine levels in mice treated for 5 days 
with aerosolized OVA only, or with OVA plus BLF501, or with OVA, BLF501 and 5 µg of an 
anti-TNF-α neutralizing antibody, administered i.p. on the 4th and 5th day of OVA 
administration (n=5 mice/group). Interestingly, the concomitant administration of anti-TNF-
α antibody blocked the protective effect of BLF501, with mice showing signs of 
inflammatory injury similar to those in OVA-treated mice (data not shown). These results 
point to a crucial role for circulating, threshold levels of TNF-α as a danger signal that 
contributes to BLF501-mediated protection in this OVA-induced model of allergic asthma. 
 
Fig. 37. Anti-inflammatory effects of orally administered BLF501 in an OVA-induced model of 
allergic asthma and involvement of dendritic cells. a, b) Levels of KC and anti-OVA IgE in sera of 
untreated mice (UNTR) or of OVA-, BLF501- and OVA plus BLF501-treated mice. Data are mean 
 S.D. (n=5/group). * p = 5.18x10-6 (a) and p = 7.33x10-6 (b) vs. OVA. c) Serum levels of TNF-α in 
a time-course experiment: peak production occurred at the same time points in both the OVA plus 
BLF501 (-●-) and the OVA-only group (-■-), but levels were consistently lower in the former. Data 
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are mean values (n=5/group). d) IL-10 levels in supernatants of lung-derived CD11c+ cells from 
untreated mice (UNTR) or OVA-, BLF501- and OVA plus BLF501-treated mice. Cells were plated 
at the same cell density for all treatment groups. Data are mean ±S.D. (n=5/group) ** p <0,001 vs. 
OVA. 
 
4.3.6.Hsp27 mediates the anti-inflammatory effects of BLF501 through induction of 
IL-10 production by dendritic cells. 
The anti-inflammatory effects of BLF501 might be due to the production of an anti-
inflammatory cytokine, such as IL-10, in response to engagement of SGLT-1, and a 
second signal, such as TNF-α. Indeed, IL-10 levels were only slightly increased in OVA-
treated animals, but markedly increased in mice treated with BLF501 and OVA. On the 
other hand, no IL-10 production was observed in mice treated only with BLF501. 
Moreover, we previously showed that anti-IL-10 antibodies abrogate the protective activity 
following SGLT-1 activation6,7. To investigate in more detail the induction of systemic IL-10 
production in response to BLF501, we tested whether dendritic cells (DCs), the main IL-
10-producing cells101, were involved in the increase of systemic IL-10 in response to OVA 
and BLF501. Thus, groups of mice (n=5/group) were treated as above with OVA alone or 
with BLF501 plus OVA; untreated mice and mice treated only with BLF501 served as 
controls. At the end of treatment, lungs were collected, enzymatically digested, and 
pulmonary CD11c+ DCs were isolated by magnetic cell sorting. After 18-h culture of these 
cells at equivalent cell densities, supernatants were collected and tested for IL-10 levels. 
The cells isolated from the BLF501 plus OVA group produced high levels of IL-10, greatly 
exceeding those from cells derived from the other groups (fig. 37 d). Moreover, the number 
of DCs obtained from mice treated with BLF501 plus OVA was significantly higher than 
that from the other groups [mean number of cells/lung ± S.D.: 4087±301 for BLF501 plus 
OVA; 216±35 for untreated (p = 6.6x10-6 vs. BLF501+OVA); 357±39 for OVA-only (p = 
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9.2x10-6 vs. BLF501+OVA); and 282±42 for BLF501-only (p = 4.8x10-6 vs. BLF501+OVA) 
(5 mice/group)]. 
Unlike epithelial cells, DCs do not express SGLT-1 and are unable to respond to BLF501 
on their own, suggesting a role for a signaling molecule in linking epithelial cell production 
of SGLT-1 with DC production of IL-10.  Based on data indicating that extracellular stress 
proteins, such as heat-shock protein (hsp) 27, act as “signaling" molecules for the innate 
immune system102 and induce anti-inflammatory mediators, including IL-10 103,  we first 
assessed hsp27 production in the culture supernatant of HT-29 human colon carcinoma 
cells stimulated with TNF-α, in the absence or presence of BLF501; high levels of hsp27 
were produced in response to TNF-α and BLF501, but not to TNF-α or BLF501 alone (Fig. 
38a).  
To test whether hsp27 production in response to BLF501 plus TNF-α was able to induce 
IL-10 production, a monolayer of HT-29 cells grown to confluence in the upper part of a 
Transwell system was co-incubated with human monocyte-derived dendritic cells (MoDCs) 
in the bottom wells, so that only molecules secreted at the basolateral side of HT-29 cells 
might reach the co-cultured MoDCs. In response to TNF-α plus BLF501, enterocytes 
induced the production of high IL-10 levels by the MoDCs (Fig. 38b). 
Consistent with the in vitro results, analysis of sera from mice treated with OVA alone or 
OVA plus BLF501 or left untreated revealed high-level production of hsp25, the murine 
analogue of human hsp27, only in the OVA plus BLF501-treated animals (Fig. 38c). 
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Fig 38. Role of hsp27/hsp25 in BLF501 activity. a) Hsp27 levels in supernatants of HT-29 human 
colon carcinoma cells in response to TNF-α, BLF501 or TNF-α plus BLF501. Data are mean ±S.D. 
(n=5/treatment) * p = 2.53x10-4 vs. TNF-α. b) IL-10 levels in supernatants of dendritic cells 
(MoDCs) in the presence of enterocytes stimulated with TNF-α, BLF501, or both, or unstimulated. 
Data are mean  S.D. (n=5/treatment) * p = 3.37x10-6 vs. TNF-α. c) Hsp25 levels in sera from 
mice treated with OVA, BLF501, or both or untreated (UNTR). Data are mean ±S.D. (n=5/group) * 
p = 1.35x10-6 vs. OVA. 
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5. DISCUSSION 
SGLT-1 is a co-transporter able to absorb D-glucose, against a concentration gradient, 
together with Na+. The expression of SGLT-1 on the apical membrane of enterocytes, the 
cells that line the gut and overlook to the intestinal lumen, is fundamental in order to obtain 
the maximum D-glucose absorption from the digested alimentary bolo that transits through 
the gut. Presented results show a novel role of SGLT-1: this protein when is appropriately 
activated modulates the immune response and protect barrier function. 
Accumulating data support the notion that SGLT1 orchestrates a number of fundamental 
cellular processes besides its canonical absorptive function. Previous reports showed that 
activation of SGLT1 induced the recruitment of GLUT2 to the brush border membrane for 
diffusive glucose transport via a PKCb-dependent pathway.103,104 Others documented that 
cotransport of Na+ with glucose triggered the activation of Akt and phosphorylation of 
cytoskeleton-associated ezrin, leading to recruitment of Na+/H+ antiport (NHE3) to apical 
membrane that facilitated absorption of sodium and hydrogen in intestines105,106 Our recent 
study demonstrated that activation of SGLT1 suppressed bacterial LPS-induced NFkB 
signaling in intestinal epithelial cells, and suggested that SGLT1 has a novel 
immunomodulatory role. Moreover, oral ingestion, but not intraperitoneal administration of 
glucose, attenuated proinflammatory cytokine production and protected endotoxemic mice 
from lethal septic shock6,7. Clinically, oral rehydration therapy that targets SGLT1 to drive 
passive diffusion of water is a widely used supportive therapy for diarrheal patients. Early 
enteral nutrition (EN) is advocated for patients with multiple pathologies for its known 
benefit in lowering the risk of septic complications compared with parenteral 
supplementation. One area that has gained much attention in nutrition therapy nowadays 
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is preoperative oral carbohydrate loading107,108. All these studies show SGLT1-mediated 
nutritive and non-nutritive functions. 
5.1 Dansyl C-Glycoside as a novel agent against endotoxic 
shock. 
The activation of the transcription factor NFkB and the production of IL-8 induced by LPS 
or CpG-ODN via TLRs is inhibited by D-glucose. This inhibition has been found to be 
mediated by the activation of sodium-dependent glucose transporter-1 (SGLT-1). 
Moreover, in a murine model of endotoxic shock, oral ingestion of glucose was found to 
protect 100% of mice6,7. These studies suggest that activated SGLT-1 may be a promising 
target for inhibition of bacteria-induced inflammatory processes and lifesaving treatments, 
assuming a novel role as an immunological player. The main drawback of this activation is 
the high level of glucose that must be administrated (2.5 g/kg) in vivo so to achieve 
protection, and the evident impacts on the metabolism. In this contest we have 
collaborated with a chemical team from in the search of non-metabolisable 
glucoderivatives able to “activate” the SGLT-1 transporter at much lower concentration, in 
order to achieve the protection against damages induced by LPSs while avoiding the 
disadvantages caused by high glucose concentration. 
A preliminary screening of the members of the library was carried out by detecting the 
level of IL-8, which is often used as quantitative marker of inflammation severity, in human 
HT29 cell line released upon treatment with LPS. Most interesting was the activity of 
compound called BLF501 that maintained the same effect on the reduction of IL-8 
production also at lowest concentration. Our results show that a significant reduction in IL-
8 release was observed for all IECs cultured in media containing BLF501 at 50 mg/l, 5 
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mg/l, 50 µg/l, 5 µg/l. At 0,5 µg/l BLF501 lose more of fifty percentuage of its anti-
inflammatory activity and at 0,005 µg/l BLF501 completely lose its activity. 
We then decided to better investigate the activity of BLF501. In order to determine the 
effective involvement of the glucose transporter-1 (SGLT-1) in the observed biological 
result just reported we carried out the detection of the level of IL-8 released upon 
treatment with LPS in human HT29 cell line SGLT-1 knockdown. SGLT-1 was silenced by 
small interfering RNA (siRNA) transfection. The silencing experiment clearly influence the 
efficacy of BLF501 in the modulation of the inflammatory processes. 
We finally investigated the effective biological activity of BLF501 in vivo. These studies 
were carried out on the mouse model of lethal septic shock. Results as expected in the 
group of mice treated only with LPS/GalNH2 induced septic shock with 100% of death 
within 36 h from the treatment, while for the group treated with LPS/GalNH2 and BLF501 a 
survival of 100% of the mice along with a behaviour comparable to untreated animals was 
observed. This result seems to confirm the great potentialities of BLF501 as inhibition of 
bacteria-induced inflammatory processes and life-saving treatments and the mice mortality 
was down to the 0%, thus achieving a life saving treatment. 
These data presented show a novel compound able to “activate” the SGLT-1 transporter, 
and seem to confirm its role as a novel immunological player. BLF501 has been 
demonstrated to be able to exert a protective effect, both in vitro and in vivo, towards 
damages induced by LPS, through it’s interaction with SGLT-1 when administrated orally 
at very low concentration. The intriguing of this work is the development of an highly active 
agonists for SGLT-1: in fact, existing molecules targeting this transporter aim to block its 
activity, in order to avoid glucose absorption into the cell. Differently, our molecule have 
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been planned as extremely effective activators of SGLT-1, given the  recent knowledge 
regarding the positive effects of its activation in inflammatory processes.  
5.2 BLF501 as a novel agent against colitis animal model. 
Our data obtained from the present study suggest that the activation of SGLT-1 from the 
novel C-Glycoside derivative BLF501, may constitute a new pharmacological agent for 
treatment of IBD. Oral administration of BLF-501 in a chemically-induced mouse model of 
acute and chronic intestinal inflammation leads to inhibition of inflammatory response and 
restore intestinal epithelial barrier function. In IBD, the observed hyper-permeable 
properties of the intestinal epithelium appear to have interwined early roles in the initiation 
of this disease. The conventional treatments for IBD as corticosteroids, mesalamine, and 
immunosuppressants, provide mostly to block downstream inflammatory events, without 
protect directly epithelial barrier. Now, novel therapies are created to address not only the 
clinical consequences of the disease but in root cause(s). Based upon this analysis 
BLF501 may be considered a novel therapeutical agent for IBD.  
Complexities of in vivo system make it difficult to determine BLF-501 effects on intestinal 
epithelial cells. Therefore we have performed a series of in vitro experiments to test 
BLF501 activity in a cultured intestinal epithelial monolayer damaged by inflammatory and 
chemically stimuli. Recently, much of the work exploring mechanisms by which intestinal 
epithelial barrier function is regulated has been performed using cultured intestinal 
epithelial cell lines. Sanders  et al.109 have shown a convenient and sensitive method to 
examine intestinal monolayer permeability. Transmonolayer movement of Fluorescein 
Dextran likely represents paracellular and not transcellular flux. In vitro studies 90 have 
shown that INF-γ and TNF-α treatment in cultured Caco-2 induces paracellular alteration 
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and increase FD-3 flux. Addition of FD of size 3 kD to apical surface of Caco-2 monolayer 
untreated leads to 23 pmole/cm2/h, but a incubation of Caco-2 monolayer with TNF-α and 
INF-γ added medium leads to increased flux at 174 pmole/cm2/h. We evaluated that 
BLF501 5 µg/l protects paracellular pathway against INF-γ and TNF-α damage. Recent 
work90 have shown that none of the seven NFk-B inhibitor  tested were able to prevent 
INF-γ/TNF-α-induced barrier dysfunction, this us leads to hypothesizes that SGLT-1 
activation protects barrier dysfunction by a mechanism that does not depend on his 
demonstrated NFk-B inhibition activity 6. Moreover data 90,91 have shown that in INF-
γ/TNF-α permeability alteration does not involve TNF-α induced apoptosis, but is mediated 
by down-regulation of tight junction protein ZO-1 and occludin. Indeed, modulation of 
permeability properties is mirrored by changes in specific TJ protein components. Images 
obtained by Confocal and Video Confocal microscopy of immunofluorescence staining of 
occludin and ZO-1 show that SGLT-1 activation by BLF501 stabilizes TJ-protein 
localization preventing INF--γ/TNF-α-mediated degradation. BLF501 is very effective at 
preventing functional (FD-3 flux) and morphological (TJ protein) permeability defects 
induced by inflammatory stimuli. 
The potential of BLF501 to ameliorate already established permeability increased was also 
examined in a second in vitro model of degradation of TJ mediated by DSS that is directly 
toxic to epithelial cells. We treated Caco-2 monolayer transwell with DSS 5% and we have 
evaluated the permeability activity of Caco-2 monolayer by measuring the paracellular 
penetration amount of FD-3 across Caco-2 monolayer. The flux of FD-3 of DSS-treated 
Caco-2 cells had increased 30-fold by 1 hour, from 50 pmole/cm2/h (control) to 270 
pmole/cm2/h  after 24 h DSS treatment. The FD-3 permeability increased following 
incubation with DSS 5%, the addition of BLF501 (5 µg/l) in apical medium significantly 
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prevented an increased in permeability to FD-3 induced by  DSS. The flux of FD-3 in BLF-
501 and DSS-treated Caco-2 cells is 20 pmole/cm2/h. BLF-501 treatment of Caco-2 
monolayer prevent DSS-induced barrier loss. Our results shows that SGLT-1 activation by 
BLF501 induce protection of barrier function that in this in vitro model is directly distrupted 
by DSS. BLF-501 protects directly TJ maintaining barrier functionality. 
In our previous work our data obtained by Ussing Chamber analysis of colon samples 
have shown that the increase in colon permeability, which may be observed in a 
enterocolitis mouse model, is avoided when animal are concomitantly treated with oral 
glucose. This results and data in vitro leads to hypothesizes that BLF-501 may be protect 
intestinal mucosal barrier in mouse model of intestinal inflammatory disease. We firstly 
have perform in vivo experiments utilizing a chemically-induced mouse model of intestinal 
inflammation, which is the most commonly used IBD animal model: feeding mice for 
several days with DSS polymers in the drinking water induces an acute colitis 
characterized by bloody diarrhea, intestinal ulcerations and infiltrations with granulocytes. 
It is generally believed that DSS is directly toxic to gut epithelial cells of the basal crypts 
and affects the integrity of the mucosal barrier. The administration of DSS at a 
concentration of 2% in the drinking water for three cycles will result in development of 
chronic colitis. The DSS-colitis model shares many clinical and pathological features of 
human ulcerative colitis with regard to ulceration and loss of barrier function. Although the 
exact action of DSS is not fully understood, it is believed that DSS causes mucosal injury 
and destroys the barrier function, leading to inflammation. DSS has been shown to 
increase mucosal permeability in mice and reduce TER in intestinal cell monolayer93-95. 
Therefore, the DSS model is an appropriate model to investigate the effect of oral 
administration of BLF-501. Using this model, we found that mice with chronic colitis BLF-
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501-treated not presents typical mucosal injury, shows a weight recovery and not develops 
severe clinical symptoms, including bleeding and dehydratation. Having shown this BLF-
501 protective effects in vitro of barrier function, we investigated the capacity of BLF-501 
oral administration to control barrier intestinal permeability in vivo. Data obtained by 
Ussing chamber analysis shown that chronic treatment with DSS leads to increased colon 
permeability compared with control mice, oral administration of BLF-501 induce in a 
intestinal permeability recovery. 
The TJ seal the paracellular space and regulate the permeability of the mucosal barrier. 
The tight junction are the ordered structure formed by multiprotein complexes consisting of 
transmembrane proteins, as occludin and nonmembrane proteins, as ZO-1. The TJ protein 
has been reported to be deregulated in IBD. We have analyzed occludin and ZO-1  
localization in colon tissue of different treatments and we have evaluated that intestinal 
permeability recovery observed with Ussing Chamber analysis is mediated by TJ protein 
protection. These results suggest that the BLF-501-mediated action involves stabilization 
of epithelial junction complex also in vivo. SGLT-1 activation plays an important role in 
restoring mucosal integrity in DSS-induced chronic intestinal inflammation. These 
reparative mechanisms could restablish intact barrier function and structure to protect the 
mucosa against entry of bacteria and forgein antigens into colonic tissue and bloodstream 
More recently, IL-10 was suggested as a potential new anti-inflammatory therapy for 
Crohn’s disease, but this treatment did not result in significantly higher remission rates or 
clinical improvement; the explanation for the failure of this therapeutic strategy is that the 
administered dose of IL-10 in clinical trials, and therefore the ultimate local IL-10 
concentration in the intestine, might be too low to down-regulate the inflammatory status96. 
We demonstrate that oral administration of BLF-501 modulates pro-inflammatory and anti-
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inflammatory cytokines in the colon, resulted in recovery of acute and chronic colitis. In the 
present study, we observed that activation of pro-inflammatory cytokines, such as TNF-α, 
and IL-12 in DSS acute and chronic colitis was suppressed by oral administration of BLF-
501. We have observed a marked increase of IL-10 levels in mice treated with BLF-501 
and acute and chronic cycles of DSS in comparison with DSS alone or with untreated 
mice. The continuous IL-10 production from immune system components, guaranteeing an 
endogenous source of this anti-inflammatory cytokine, is able, to down-modulate the 
inflammatory response, avoiding the problems linked to the classical IL-10 therapy. 
5,3 BLF501 as a novel agent against inflammatory lung 
disease. 
Our results in two experimental models of inflammatory lung disease, i.e., mice exposed to 
aerosolized LPS and the model of OVA-induced asthma, show that engagement of the 
glucose transporter SGLT-1 induces potent anti-inflammatory effects in lungs. As an 
SGLT-1 ligand, we used the synthetic glucose analogue BLF501, a synthetic C-glucoside 
derivative, identified by in vitro screening for SGLT-1 ligands that might elicit anti-
inflammatory effects similar to those induced by glucose but at much lower concentrations 
compatible with possible therapeutic applications. 
In the first model analyzed, exposure of mice to aerosolized LPS led to acute respiratory 
distress, accompanied by widespread destruction of the alveolar and endothelial epithelia, 
as well as flooding of the alveolar spaces with proteinaceous exudates containing large 
amounts of neutrophils110-112. This is the consequence of LPS binding to TLRs, followed by 
the expression of proinflammatory cytokines (TNF-α and IL-1β), chemokines (keratinocyte-
derived chemokine KC or IL-8, and adhesion molecules (ICAM-1 and vascular cell 
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adhesion molecule-1 VCAM-1), which induce the extravasation of neutrophils across 
endothelial and epithelial barriers that separate the bloodstream from the pulmonary air 
spaces110,111. By contrast, mice treated with LPS and aerosolized BLF501 presented a 
normal lung parenchyma, without cellular depots within the alveoli. Immunohistochemical 
analysis of lung sections showed a marked increase in ICAM-1 and caveolin expression in 
mice treated with LPS alone, but not upon treatment with LPS and BLF501. Moreover, 
analysis of the BALFs revealed high levels of NO in LPS-treated animals, but not in mice 
also treated with BLF501. It is noteworthy that the engagement of SGLT-1 by BLF501 per 
se did not influence inflammatory parameters since mice receiving BLF501 alone were 
comparable in all respects to untreated control mice.  
A similar protective activity of BLF501 was observed in OVA-induced allergic asthma, a 
model that differs considerably from LPS-induced lung injury with respect to pathogenesis 
but not in the inflammatory outcomes, including the abundant cellular infiltrates in lung 
parenchyma and increased serum levels of pro-inflammatory chemokines and cytokines. 
Lung tissue from BLF501-treated mice did not exhibit depots of alveolar lymphocytes or 
blood infiltrates, and BALFs revealed no accumulation of neutrophils or eosinophils. The 
reduction of leukocyte in filtration observed in OVA plus BLF501 treated mice may play a 
pivotal role in the induction of anti-inflammatory effects observed in this setting, since 
neutrophils are considered primary effector cells in the alveolo-capillary damage that 
accompanies lung inflammation112. Moreover, serum levels of  IL-4 and IL-5, prototypical 
cytokines involved in the pathogenesis of asthma, and of IgE were elevated in mice 
treated with OVA alone but normal  in OVA plus BLF501-treated mice, which also showed 
dramatically increased serum levels of the anti-inflammatory cytokine IL-10. 
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A high protein content was observed in the BALFs from mice treated with OVA alone, 
consistent with the presence of high-permeability pulmonary edema, whereas BALF 
protein concentrations in BLF501-treated mice was comparable to that of untreated mice 
or mice treated with BLF501 alone. Thus, BLF501 effectively decreased abnormal lung 
vascular permeability and promoted resolution of lung edema, suggesting that this reagent 
protects the integrity of the alveolo-capillary membrane. 
BLF501 had protective activity in OVA-induced asthma even when orally administered, 
while intravenous administration did not lead to a protective effect. These findings 
suggested an engagement of SGLT-1 expressed in intestinal epithelial cell by orally 
administered BLF501 that induces a direct or indirect release of anti-inflammatory 
molecules.  In fact, mice orally treated with BLF501 and OVA had very high systemic 
levels of  IL-10, an anti-inflammatory cytokine produced mainly by DCs and monocytes113. 
Accordingly, administration of recombinant IL-10 has been shown to increase survival in 
mice undergoing sepsis, while IL-10 gene therapy significantly attenuates sepsis-induced 
multi-organ failure114. Thus, IL-10 produced by DCs and monocytes would be the final 
mediator of the systemic anti-inflammatory effects induced by BLF501, which, though 
orally administered, exerts anti-inflammatory activity in the lung compartment through 
these soluble mediators. DCs do not express SGLT-1, but they produce IL-10 when 
activated by hsp27115,116. Our in vitro data showed that hsp27 is strongly secreted by 
SGLT-1-positive epithelial cells HT-29, upon stimulation with TNF-α in the presence of 
BLF501, and the co-culture of TNF-α/ BLF501-treated HT-29 cells with MoDCs cells led to 
the production of high levels of IL-10 by DCs.  This production of IL-10 was completely 
eliminated upon silencing of hsp27 expression in HT29 cells . In vivo, hsp 25 serum levels, 
murine homologue of hsp27, were dramatically increased in mice treated with OVA and 
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BLF501. Together, these findings strongly suggest that hsp25/hsp27 mediates activation 
of SGLT-1 and production of IL-10 by DCs. 
The present data showing that BLF501 exerts potent anti-inflammatory effects in two 
different experimental models of inflammatory lung diseases provide direction to a new 
pharmacological approach for treatment of inflammatory lung diseases. Thus, the SGLT-1 
ligand synthetic glucose analogue BLF501 might serve in the therapeutic intervention of 
lung inflammation, especially in allergic asthma, a disease of increasing world-wide 
prevalence with still unmet clinical needs. 
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